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ABSTRACT 
Cutaneous melanoma is a highly aggressive disease resistant to conventional 
treatment and characterized by poor prognosis. Targeted therapies against MAPK 
pathway and immune checkpoint inhibitors have dramatically improved survival of 
metastatic melanoma patients but the extent and duration of response are variable. 
Classification based on gene expression profiling have so far allowed identification of 
melanoma subtypes with distinctive biological features and with potential clinical impact. 
However, clinical translation of molecular subtypes is hampered by inconsistencies 
among the different classifications. 
Here, through a harmonized bioinformatic analysis of public transcriptomic 
datasets, we compared and combined nine published classification systems to derive the 
consensus transcriptional subtypes of melanoma. Beyond confirming previously reported 
subtypes, our approach enabled the identification of a novel highly mitotic, 
chromosomally unstable group of melanomas that recapitulated a transitory state from a 
proliferative, melanocytic, differentiated phenotype to a more mesenchimal invasive 
program. We provided evidence that this classification has a prognostic role in metastatic 
melanoma patients, independently from the levels of tumour immune infiltration. We 
translated consensus subtypes to in vitro melanoma cell lines and combining them with 
pharmacological data we highlighted subtype-specific sensitivity to MAPK inhibitors and 
other drugs. Analysis of baseline gene expression data of metastatic melanoma patients 
treated with MAPK or immune checkpoint inhibitors showed that the predictive role of 
consensus subtypes in clinical setting remains to be elucidated. Finally, through the 
analysis of multi-omics data from the same set of patients, we comprehensively 
characterized the consensus subtypes at the genomic, transcriptional, and epigenomic 
levels.  
Our results showed that melanoma gene expression classifications converged on 
five biological entities determined by transcriptional and epigenetic events, and with 
potential implications for prognostication. 
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1 INTRODUCTION 
1.1 Melanoma epidemiology and risk factors 
Melanoma is a relatively uncommon cancer but its worldwide incidence has been 
increasing faster than any other cancer type in the last 50 years (Ali et al., 2013). For 
2018, approximately 287,723 new melanoma cases and 60,712 melanoma-related deaths 
are estimated (Bray et al., 2018). Although melanoma accounts for only 5% of all 
dermatological malignancies, its highly metastatic potential makes it the most lethal form 
of skin cancer. Incidence rates vary widely across countries and these variations are 
related to differences of complexion across ethnic groups and patterns of sun exposure. 
Melanoma is more frequent in the Caucasian population with light skin complexion due to 
lower melanin production and consequently decreased photoprotection. On the other 
hand, darker-pigmented individuals have a higher tanning ability and higher protection 
against ultraviolet- (UV-)A and UV-B radiation (Brenner and Hearing, 2008). Within the 
same ethnic group, melanoma incidence varies by geographic location (Figure 1.1) as 
many factors, like altitude, latitude and cloud cover, can influence UV radiation intensity. 
The highest incidence worldwide is observed in New Zealand and Australia with an annual 
age-standardized rate (ASR) of 33.6 and 33.3 cases per 100,000 inhabitants 
(http://gco.iarc.fr/today/). In Europe, Norway (29.6:100,000 cases per year), Denmark 
(27.6:100,000 cases per year), and Sweden (24.7:100,000 cases per year) have the highest 
ASR (http://gco.iarc.fr/today/). Southern countries, like Italy (12.4:100,000 cases per year) 
and Spain (6.4: 100,000 cases per year), have a lower ASR compared to Scandinavian 
countries. This difference is partially related to increased protection against UV radiation 
in darker skinned people from Southern Europe compared to fair skin people typical of 
Scandinavian countries. 
In relation to age, melanoma affects young and middle-aged people with a median 
age at diagnosis of 57 years. Worldwide, melanoma ASR increases linearly with age, even 
if in the United States the highest incidence rate is observed in the sixth decade of life and 
then decreases (Matthews et al., 2017). Melanoma incidence is also related to sex, with 
men being in general more affected than women (Matthews et al., 2017). When sex and 
age are considered together it is observed that women develop melanomas at younger 
age, while men are more affected after the age of 40 (Rastrelli et al., 2014). This may be 
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partially explained by a more frequent usage among young women of artificial tanning 
that increases the risk of melanoma (Zhang et al., 2012). 
 
Figure 1.1. Geographical distribution of estimated age-standardized incidence rates for skin melanoma. 
Both sexes and all ages are considered. Source: http://gco.iarc.fr/today/. 
Epidemiological studies have identified several environmental and individual 
melanoma risk factors, and their interplay explains the high variation in disease 
demographics. The most important environmental risk factor is UV radiation and 
especially UV-B levels. The timing and pattern of sun exposure is relevant in determining 
the risk of developing melanoma during the life span. A number of epidemiological 
studies have shown that intense and intermittent UV exposure is associated to a higher 
risk of melanoma (Gilchrest et al., 1999; Elwood and Jopson, 1997). In addition, 
intermittent sun exposure and sunburns in childhood and adolescence increase the risk of 
melanoma development (Whiteman et al., 2001; Holman and Armstrong, 1984). Exposure 
to artificial UV-A radiation has been linked to the development of melanoma. Individuals 
using sunbeds, especially in the young age, or receiving psoralen-UV-A radiation 
photochemotherapy for the treatment of psoriasis have an increased risk of melanoma 
(Stern, 2001; Cust et al., 2011; Veierod et al., 2010). No other environmental risk factors, 
including tobacco consumption (Merimsky and Inbar, 1998), have been associated with 
melanoma risk (Ali et al., 2013). 
Melanoma susceptibility is increased by individual risk factors including congenital 
or acquired melanocytic nevi, familial history of melanoma, genetic susceptibility and 
previous melanoma diagnosis. The risk of melanoma is positively correlated with the 
number and size of melanocytic nevi (Holly et al., 1987; Grob et al., 1990). About 25% of 
melanomas, indeed, arise from a pre-existing nevus (Bevona et al., 2003). A family history 
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of melanoma constitutes a strong risk factor for the disease and is linked to the 
transmission of predisposing genetic mutations (Goldstein and Tucker, 2001). Germline 
mutations in the two suppressor genes CDKN2A and CDK4 are the two most frequent 
alterations found in individuals from melanoma-prone families (Gruis et al., 1995; Tsao 
and Niendorf, 2004). Additional inherited diseases including xeroderma pigmentosum, Li-
Fraumeni cancer syndrome, familial retinoblastoma and Lynch syndrome type II confer 
higher risk of melanoma (Goldstein and Tucker, 2001). 
Individuals with reduced protection from UV radiation due to fair skin, red hair and 
light eyes have a higher risk of developing melanoma (Titus-Ernstoff et al., 2005). This 
phenotype is conferred by the presence of loss of function polymorphisms in the 
melanocortin 1 receptor (MC1R) gene. These polymorphisms impair the synthesis of 
melanin and confer reduced ability to tan and photo-protection (Sturm, 2002; Kanetsky et 
al., 2006). A personal history of melanoma increases the chance of developing further 
primary melanomas (Levi et al., 2005; DiFronzo et al., 1999). 
1.2 Melanoma staging and prognostic stratification 
Staging is based on the TNM classification system where T refers to the features of 
the primary tumour, N to the number of nearby lymph nodes affected by cancer and M to 
the presence of metastases. Guidelines for melanoma staging are delineated by the 
American Joint Committee on Cancer (AJCC) with the last updated version published in 
2017 (eighth edition) (Gershenwald et al., 2017).  
The TNM classification provides a detailed description of the disease. The T-
category stratification is defined by two independent prognostic factors: tumour 
thickness and ulceration (Table 1.1). Tumour thickness, also known as Breslow index 
(Breslow, 1970), is associated with worse outcome (Balch et al., 2009). Ulceration is a 
condition in which the dermis overlying the primary tumour is not intact according to 
microscopic evaluation of the tissue. The presence of ulceration is associated to a more 
aggressive phenotype and worse prognosis (Balch et al., 1980; McGovern et al., 1982). 
The number of lymph nodes affected by metastases defines the N-category that is further 
stratified in “a”, “b”, or “c” depending on the regional tumour burden (presence of 
clinically occult or clinically detected metastases) or presence of in-transit or satellite 
metastases (Table 1.1). The site of the metastases is used to stratify patients in four M1 
subgroups, from “a” to “d” (Table 1.1). 
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TNM classification is used for prognostic stratification of patients in five stages 
with corresponding subgroups (Table 1.2). Stage 0 melanomas are known as melanoma in 
situ and are the earliest form of melanoma. Tumour cells are confined to the epidermis 
and have not spread to the surrounding tissue, lymph nodes or distant sites. Patients with 
melanoma in situ have a low risk of developing a local recurrence or metastases and 
surgery is curative in the majority of cases. Stage I and stage II melanomas are localized 
tumours that have grown deeper in the skin but have not spread to the lymph nodes or to 
distant sites. Patients with localized melanoma are usually cured by surgery and have a 5-
year survival rate of 98.4% (Noone et al., 2017). Stage III melanomas are tumours that 
have spread to regional lymph nodes or have developed in-transit or satellite metastasis 
with no evidence of distant metastasis. According to the AJCC staging system, there are 
four stage III subgroups (A, B, C, and D) depending on primary tumour thickness and 
ulceration, number of lymph nodes affected by metastases, the regional tumour burden, 
and the presence of in-transit or satellite metastases (Gershenwald et al., 2017) (Table 
1.1). Similarly to localized melanomas, tumour thickness and ulceration of the primary 
tumour are independent predictors of worse survival for patients with stage III melanoma 
(Gershenwald et al., 2017). The survival rate of patients with stage III disease is 
heterogeneous with five-year melanoma-specific survival ranging from 93% for patients 
with stage IIIA melanoma to 32% for stage IIID disease (Gershenwald et al., 2017). Stage 
IV melanomas are associated with metastases beyond regional lymph nodes that have 
reached distant sites (M1). The 5-year survival of stage IV melanoma patients is 22.5% 
(Noone et al., 2017). Another important prognostic factor for stage IV melanoma is the 
serum level of lactate dehydrogenase (LDH) that adds a further designation of the M-
category. According to LDH, patients are assigned to the 0 group (not elevated LDH) or 1 
group (elevated LDH) with the latter defining a decreased survival rate among stage IV 
patients. 
In addition to the AJCC staging system other factors such as age at diagnosis, sex, 
primary tumour site and number of distant metastases have been shown to be of 
prognostic relevance. Older age at diagnosis is generally associated to worse primary 
tumour features, such as increased Breslow index and presence of ulceration, and 
decreased overall survival (Balch et al., 2013; Chao et al., 2004). Among melanoma 
patients, females have generally better outcome compared to men. The reason of this 
difference is not well understood but a possible explanation could be the younger age at 
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disease and the difference in tumour site (Joosse et al., 2012; Joosse et al., 2013). The site 
of primary tumour is another prognostic factor with lesions arising on the trunk and head 
and neck associated with worse survival despite they have a lower rate of positive 
sentinel lymph nodes (Fadaki et al., 2013). 
Beyond traditional clinical and histological parameters molecular prognostic 
signatures have been identified through the use of gene expression microarrays. 
Numerous gene expression-based prognostic signatures have been reported in the 
literature (Winnepenninckx et al., 2006; John et al., 2008; Bogunovic et al., 2009; Conway 
et al., 2009; Jonsson et al., 2010; Mann et al., 2013), and despite their little overlap in 
terms of genes they were shown to converge on the role of immune system in 
determining a better prognosis (Schramm et al., 2012). Although gene expression 
signatures seem a promising tool for prognosis, their translation in the clinical use has not 
yet been realized due to lack of agreement between signatures, poor validation and 
assessment of their performance in comparison to current clinic-pathologic markers of 
outcome. 
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Table 1.1. TNM classification according to the AJCC staging system (Gershenwald et al., 2017). 
 
 
Table 1.2. Pathological stage grouping according to the AJCC staging system (Gershenwald et al., 2017). 
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1.3 Current treatment options in melanoma 
Treatment options for melanoma have changed in recent years. The choice of the 
treatment depends on the stage and location of the disease, the presence of specific 
genetic alterations affecting tumour cells, and the overall patient’s health conditions. 
1.3.1 Conventional treatments: surgery and chemotherapy 
For patients with early-stage melanoma (stage 0-IIIB) surgical excision is the 
primary treatment and in most cases is curative (Ross and Gershenwald, 2011). The 
surgery procedure occurs through a wide local excision of the tumour with specific safety 
margins depending on the thickness of the melanoma. When melanoma is thicker than 1 
mm or 0.8 mm with ulceration, a sentinel lymph node (SLN) biopsy can be performed to 
assess the dissemination of the disease to surrounding lymph nodes (Wong et al., 2018). 
If the SLN is positive for tumour cells, completion lymph node dissection (CLND) is 
recommended to remove all the remaining lymph nodes. However, different studies that 
evaluated the outcome of patients who did or did not undergo CLND showed no 
differences in survival between the two groups (Kingham et al., 2010; Leiter et al., 2016; 
Fioranelli et al., 2017). In stage IV melanoma surgical removal of metastases is rarely 
proposed if not for palliative care, but metastasectomy could bring survival benefit in 
carefully selected patients (Sosman et al., 2011; Wei et al., 2014; Martinez and Young, 
2008).  
The use of cytotoxic chemotherapeutic agents has been the earliest 
pharmacological treatment option for advanced melanoma. Until 2011, Dacarbazine, an 
alkylating agent approved in 1974 by the Food and Drug Administration (FDA) agency, 
was the only standard pharmacological option for patients with metastatic melanoma, 
but the overall response rate was < 20% with median response duration of 5-6 months, 
complete response < 5% of cases and a 5-year survival achieved in 2%-6% of patients 
(Serrone et al., 2000; Kim et al., 2010). Since FDA approval, dacarbazine has been tested 
in combinations with many other drugs, but no clinically meaningful improvements in 
survival have been observed (Eggermont and Kirkwood, 2004). Another 
chemotherapeutic drug used for advanced melanoma treatment is temozolomide, an oral 
prodrug of the active metabolite of dacarbazine. Given its small size and lipophilic 
properties it can cross the blood-brain barrier thus being more effective for the treatment 
of brain metastases (Agarwala and Kirkwood, 2000). Compared to dacarbazine, 
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temozolomide has similar response rate and median overall survival (Middleton et al., 
2000; Patel et al., 2011). 
1.3.2 Targeted therapies 
Ongoing research has identified several genetic mutations affecting key signaling 
pathways in melanoma. This has led to the development of small molecule inhibitors that 
target these mutated proteins, which are important for the progression of the disease. 
In 2002, it has been discovered that BRAF is the most frequently mutated gene in 
melanoma (Davies et al., 2002). BRAF is a serine-threonine kinase acting in the mitogen-
activated protein kinase (MAPK) signaling pathway that control proliferation and survival 
of cells. Mutations in the BRAF gene are associated to constitutive pathway activation, 
resulting in enhanced growth and proliferation of cancer cells. The most common BRAF 
mutation is BRAFV600E where amino acid 600 changes from the normal valine to glutamic 
acid. Other less frequent mutations at this site are valine-to-lysine (BRAFV600K) and valine-
to-arginine (BRAFV600R) substitutions.  
Vemurafenib was the first BRAF-mutant inhibitor approved by FDA in 2011 for the 
treatment of unresectable stage III or stage IV melanoma patients harboring BRAFV600E 
mutation. Compared to dacarbazine, vemurafenib showed superior overall response rate, 
progression-free and overall survival in clinical trials including unresectable stage III/IV 
melanoma patients with BRAFV600E/K mutations (Chapman et al., 2011; Sosman et al., 
2012). Another inhibitor of BRAF-mutant protein is dabrafenib that was approved by FDA 
in 2013 for the treatment of patients with unresectable or metastatic melanoma with 
BRAFV600E/K mutations. Dabrafenib showed similar beneficial effects of vemurafenib 
(Hauschild et al., 2012). 
Inhibition of the MAPK pathway activity can be reached through the inhibition of 
downstream effectors of BRAF. MEK is a downstream target of BRAF and in 2013 the FDA 
approved the MEK inhibitor trametinib for the treatment of unresectable stage III/IV 
melanoma possessing BRAFV600E/K mutations. In BRAF-mutant metastatic melanoma, 
trametinib showed improved progression-free and overall survival as compared to 
chemotherapeutic treatment (Flaherty et al., 2012). In 2015, FDA approved another MEK 
inhibitor, cobimetinib, to be used in combination with the BRAF inhibitor vemurafenib for 
the treatment of BRAF-mutant melanomas that cannot be surgically removed or have 
already metastasized. This combinatorial therapy showed a significant improvement of 
progression-free survival compared to vemurafenib alone (Larkin et al., 2014). 
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Although targeted therapies have improved survival of patients with advanced 
melanoma, durable responses are not observed and most patients develop resistance 
(Trunzer et al., 2013). Furthermore, about 20% of patients lack anti-tumour response to 
BRAF inhibitors due to intrinsic resistance (Van Allen et al., 2014). Many mechanisms of 
resistance have been described. These include reactivation of the MAPK and PI3K-AKT 
pathways through MEK (Wagle et al., 2011; Trunzer et al., 2013) and NRAS (Nazarian et 
al., 2010) mutations, BRAF-mutant amplification (Shi et al., 2012), loss of NF1 (Whittaker 
et al., 2013) or PTEN (Paraiso et al., 2011), splicing variants of BRAF transcript (Poulikakos 
et al., 2011), activation of COT kinase (Johannessen et al., 2010), disrupted feedback 
regulation (Lito et al., 2012), receptor tyrosine kinases up-regulation (Kabbarah et al., 
2010; Villanueva et al., 2010), and sustained signaling through stromal secretion of HGF 
(Straussman et al., 2012). In addition, intra-tumour heterogeneity can contribute to 
therapeutic failure. Cancer cells with different molecular alterations can coexist within 
the same tumour and treatment can induce a selective pressure that can enhance the 
expansion of subclones with features of resistance (Yancovitz et al., 2012; McGranahan 
and Swanton, 2017). 
Another type of targeted therapy includes immune checkpoint inhibitors, 
antibodies that indirectly affect the tumour by targeting immune inhibitory molecules, 
preventing their binding to ligands and boosting the anti-tumour immune response. 
Melanoma is one of the most immunogenic malignancies with a high mutational burden 
that has been associated with response to immunotherapy in multiple cancer types. Thus, 
melanoma results a good candidate for this type of treatment. The first immune 
checkpoint inhibitor approved by FDA in 2011 was the anti-CTLA-4 monoclonal antibody 
ipilimumab, after reports of improved overall survival in patients with previously treated 
metastatic melanoma (Hodi et al., 2010). CTLA-4 is a receptor expressed on activated T-
cells that, following ligand binding, down-regulates the extent of T-cell activation. (Brunet 
et al., 1987). Targeting PD-1, another immune checkpoint receptor, and its ligands, 
programmed cell death ligand 1 (PD-L1) and PD-L2, is also emerging as a promising 
immunotherapeutic modality (Okazaki and Honjo, 2006). Compared to targeted therapy, 
immune checkpoint inhibitors show higher toxicity and lower rapidity of response but 
they can achieve more long-lasting responses (Ratterman et al., 2016). Two anti-PD-1 
monoclonal antibodies, nivolumab and pembrolizumab, were approved by FDA in 2014 
for the treatment of patients with unresectable stage III or metastatic melanoma, or 
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patients progressing after receiving ipilimumab. Compared to ipilimumab, they provide 
better outcome and less toxicity (Wolchok et al., 2017; Schachter et al., 2017). 
1.4 Melanocytes and melanomagenesis 
Melanocytes are neural crest-derived cells present in the basal layer of epidermis 
and in hair follicles (Miller and Mihm, Jr., 2006). A considerable number of melanocytes 
can also be found in the uveal tract of the eye and at lower density in other tissues such 
as mucosal surfaces and meninges. The principal role of melanocytes is to provide 
protection from UV radiations through the production of melanin (Sturm, 1998) (Figure 
1.2). Upon UV-induced DNA damage, skin keratinocytes secrete the α-melanocyte 
stimulating hormone (α-MSH) that binds MC1R on melanocytes (Swope et al., 2014). 
MC1R activates the transcription of micropthalmia-associated transcription factor (MITF), 
which in turn induces the expression of melanin synthesis genes and stimulates melanin 
production (Chen et al., 2014). Melanin is delivered to surrounding keratinocytes through 
melanosomes and protects them from further DNA damage by scattering and absorbing 
UV radiation. 
 
Figure 1.2. Cellular response to UV-radiation. In response to sun exposure keratinocytes synthesize the 
pro-opiomelanocortin (POMC) polypeptide in a p53-dependent manner. POMC is processed into its active 
components: α-melanocyte stimulating hormone (α-MSH), adrenocorticotropic hormone (ACTH), and β-
endorphin. α-MSH binds to the MC1R receptor on melanocytes that produce melanin through the 
activation of pigment-related genes regulated by MITF. 
Melanocytes produce two types of melanin: the black/brown eumelanin and the red 
pigment pheomelanin. Their ratio confers the large variety of skin pigmentation in 
humans. After UV absorption, pheomelanin produces reactive oxygen species (ROS) that 
can affect melanocytes physiological processes and can induce DNA damage if not 
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counterbalanced by the black eumelanin (Morgan et al., 2013). Thus, eumelanin 
contributes to DNA damage defense by absorption of UV radiation and ROS elimination. 
The malignant transformation of melanocytes is the result of the accumulation of 
mutations leading to uncontrolled growth and of a deregulated interaction with the 
tumour microenvironment. This process follows a sequential genetic model that results in 
the constitutive activation of oncogenic signaling pathways. The activating BRAFV600 
mutation is the most frequent alteration found in melanomas and benign nevi, suggesting 
that this mutation occurs early during transformation. However, melanocytes harboring 
BRAF or NRAS mutations undergo oncogene-induced senescence (Michaloglou et al., 
2005). This suggests that BRAF or NRAS mutations alone cannot give rise to malignant 
cells. Further events are required to overcome the senescent state. Progression to 
melanoma in situ requires additional mutations such as mutations in TERT promoter, 
mutations or loss of CDKN2A or PTEN. The TERT gene encodes telomerase reverse 
transcriptase, the catalytic subunit of telomerase. This enzyme plays a key role in 
telomere maintenance during embryonic development but it is repressed in most adult 
somatic cells. Re-expression of telomerase enables cancer cells to overcome the anti-
proliferative effect of telomeres shortening during cell replication. CDKN2A locus encodes 
two proteins (p16INK4A and p14ARF) that suppress cell proliferation in presence of DNA 
damage or oncogene activation. PTEN encodes a phosphatase that functions as a tumour 
suppressor by negatively regulating the AKT/PKB signaling pathway. In this phase, 
melanoma cells are confined to the epidermis and they still do not have metastatic 
properties. Surgical excision of these lesions is associated with high cure rates. 
Accumulation of events that disrupt the control of cell migration and adhesion leads to 
the vertical growth phase, where melanoma cells start to grow vertically and invade the 
dermis. This phase is accompanied by loss of E-cadherin and expression of N-cadherin and 
integrins that facilitate the remodeling of the extracellular matrix and promote invasion 
(Hsu et al., 1996; Sanders et al., 1999). Melanoma becomes metastatic when tumour cells 
dissociate from the primary tumour, invade surrounding vascular and lymphatic 
structures and disseminate throughout the body to form a tumour in other tissues. 
Usually, melanoma metastases are found first in the proximal lymph nodes while 
metastases at distant sites appear later. This suggests a progressive model of metastatic 
spreading, but evidence shows that the metastatic process can start at earlier stages from 
the dissemination of melanocytic nevi (Shain and Bastian, 2016; Sanborn et al., 2015). 
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1.5 Molecular classification of melanoma 
Historically, tumour classification has been primarily based on histological features 
and evaluation of single biomarkers. It is generally accepted that the different clinical 
courses of patients with histologically identical tumours is a result of molecular 
differences among cancers. The advent of high-throughput technologies such as 
microarrays, first, and next-generation sequencing (NGS), subsequently, has 
revolutionized the way of looking at cancer heterogeneity making possible to obtain the 
molecular profile of tumours on a genome-wide scale. Gene expression profiling has been 
proven to be a valuable tool to identify and predict cancer subtypes (Golub et al., 1999). 
In melanoma, many transcriptomic studies have been reported. Bittner and colleagues 
(Bittner et al., 2000) published in 2000 the first study reporting a molecular classification 
of cutaneous melanoma. Analyzing the transcriptional profiles of metastatic melanoma 
biopsies and cell lines using an early cDNA microarray platform, they identified through 
unsupervised analysis two subtypes of melanoma with a major cluster characterized by 
reduced expression of genes involved in motility and invasion. This finding was further 
supported by an independent study that identified two subtypes of metastatic melanoma 
with opposite gene expression patterns (Haqq et al., 2005). With the improvement of 
microarray technology this classification was further investigated in numerous 
transcriptomic studies (Table 1.3). In vitro experiments showed that one of the two 
subtypes was characterized by high proliferation and low motility and capacity to invade 
(Hoek et al., 2006); the opposite pattern of gene expression observed in the other group 
translated in low proliferation and high invasiveness (Hoek et al., 2006). The proliferative 
subtype was characterized by Wnt/β-catenin signaling, leading to up-regulation of MITF, 
the master regulator of melanocytic differentiation, and its target genes such as melan-A 
(MLANA), tyrosinase (TYR), dopachrome tautomerase (DCT) (Hoek et al., 2006). The 
invasive subtype showed down-regulation of these genes and high expression of TGFβ-
regulated genes that inhibit Wnt signaling, such as WNT5A, and genes involved in the 
remodeling of the extracellular matrix (ECM) (Hoek et al., 2006). Moreover, the invasive 
capacity of this subtype was associated to the up-regulation of the receptor tyrosine 
kinase AXL that was expressed at high levels in MITF-negative (AXL-positive) tumours and 
down-regulated in proliferative melanomas (AXL-negative) (Sensi et al., 2011). Through 
immunohistochemical staining, and more recently by single-cell RNA sequencing, it was 
demonstrated that the two phenotypes can coexist within the same melanoma lesions 
13 
 
(Eichhoff et al., 2010; Tirosh et al., 2016). Overall, these findings led to the generation of 
the phenotype switching model. According to this model, cells that are in a proliferative 
state and thus contribute to tumour growth, can respond to specific microenvironmental 
signals and shift toward an invasive phenotype, giving them the ability to metastasize. 
Once an invasive cell has migrated to another site, it can shift back to a proliferative state 
and give rise to a metastatic lesion (Hoek et al., 2008; Hoek and Goding, 2010; Carreira et 
al., 2006). The mechanism of phenotype switching not only explains the possible 
dynamics of the metastatic process, but it was shown to be a determinant of resistance to 
MEK and BRAF inhibitors with the invasive subtype being less sensitive to these drugs 
(Zipser et al., 2011; Konieczkowski et al., 2014; Muller et al., 2014). 
Over the years, new gene signatures discriminating the two melanoma subtypes 
have been derived, providing new insight into the molecular mechanisms and regulatory 
precesses at the basis of phenotype switching (Verfaillie et al., 2015; Rambow et al., 
2015). Verfaillie and colleagues (Verfaillie et al., 2015) applied unsupervised clustering to 
gene expression data of melanoma clinical samples and identified two main subtypes that 
mirrored the proliferative/invasive states observed in vitro (Hoek et al., 2006). They 
identified a more comprehensive phenotype switching-related gene signature partially 
overlapping with the list obtained by Widmer et al (Widmer et al., 2012). In addition, 
through an extensive in vitro and in silico analysis of the chromatin landscape and 
transcriptome of melanoma cell lines, they identified TEAD factors as the master 
regulators of the invasive state. Subsequently, Rambow and co-workers (Rambow et al., 
2015) applied a pan-cancer bioinformatics approach to transcriptomic data of cell lines 
and clinical tumours to identify melanocyte lineage-specific gene and microRNA 
signatures of invasion and proliferation. 
Additional studies showed that the dual melanoma classification can be further 
refined with the identification of biologically meaningful subgroup within each subtype. 
According to the expression of RTKs, we identified two subset of the invasive state 
distinguished by opposite expression of ERBB3 and EGFR (Dugo et al., 2015). In a very 
recent work, Tsoi and colleagues identified four subtypes of melanoma cell lines that 
recapitulate the different steps of the melanocytes differentiation trajectory (Tsoi et al., 
2018). Two subtypes, the transitory and the melanocytic, showed features of a 
proliferative state such as low expression of AXL and high expression of MITF, with a 
stronger expression of MITF-target genes in the latter group. On the other hand, the 
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undifferentiated and the neural crest-like subtypes presented down-regulation of MITF 
and up-regulation of AXL and overlapped with the EGFRhigh/ERBB3low and EGFRlow 
/ERBB3high invasive subtypes that we previously described (Dugo et al., 2015). In addition, 
they showed that differentiation of melanoma cells was negatively correlated to 
susceptibility to ferroptosis-inducing drugs. 
Beside a better knowledge in melanoma biology, molecular subtypes can be also 
relevant for prognostication of melanoma patients. Gene expression analysis of 57 stage 
IV melanoma patients led to the identification of four subtypes associated with overall 
survival (Jonsson et al., 2010). These subtypes partially overlapped with the 
invasive/proliferative classification and showed that high tumour immune infiltration is a 
predictor of good outcome, as previously reported (Bogunovic et al., 2009). The Cancer 
Genome Atlas consortium reported a stratification of melanoma patients based on 
whole-exome sequencing mutational analysis (The Cancer Genome Atlas Network, 2015). 
According to the pattern of the most frequently mutated genes, four subtypes were 
defined: mutant BRAF, mutant RAS, mutant NF1 and triple wild-type (WT). Despite this 
genomic classification can guide the choice of the best targeted treatment, it was not 
associated to patient’s outcome. However, in their comprehensive molecular 
characterization of melanoma, TCGA identified three transcriptional subtypes: keratin, 
MITF-low and immune. The MITF-low and keratin groups corresponded to the invasive 
and proliferative subtypes, respectively, with the latter being associated to the worst 
overall survival. The immune subtype, similarly to the high-immune group identified by 
Jonsson and colleagues, showed marked expression of immune-response related genes 
and had the best overall survival (The Cancer Genome Atlas Network, 2015). In 
agreement with previous studies (Hoek et al., 2006; Widmer et al., 2012; Verfaillie et al., 
2015), the genomic and transcriptomic subtypes identified by TCGA were not correlated, 
supporting the notion that genomic alterations are not the main determinants of the 
transcriptional phenotype of melanoma cells.  
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 Table 1.3. Summary of gene expression-based classification systems. The signatures are listed according 
to the date of publication. 
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2 AIMS 
Melanoma is a heterogeneous disease at the clinical, histopathological and molecular 
levels. Classification is a key topic in oncology to better stratify patients and improve the 
prediction of outcome and design novel therapeutic strategies. Transcriptomic studies 
have shown that melanoma can be classified in distinct molecular subtypes characterized 
by specific gene expression signatures. These classifications may integrate the current 
pathological classifiers to improve the understanding of melanoma biology and to assist 
clinicians in prognosis assessment and therapeutic decision making. However, such 
approaches are difficult to translate from bench to bedside due to inconsistencies among 
the different signatures and lack of extensive analytical and clinical validation. The 
merging of the different classifications into a single consensus stratification system is a 
crucial step to facilitate the translation of molecular subtypes into the clinical practice. At 
present, the published melanoma gene expression classifiers have not yet been 
integrated in a consensus subtyping scheme.  
The research work described in this thesis has the purpose to derive a consensus 
molecular classification of melanoma through a meta-analysis of published gene 
expression-based classifiers and of publicly available transcriptomic data. Specifically, 
three tasks have been addressed: 
 To derive and validate a new consensus molecular classification of melanoma 
combining nine previously published melanoma subtyping systems and to identify 
the biological pathways distinctive of consensus subtypes; 
 To evaluate the prognostic impact of consensus subtypes and their ability to 
predict response to drug treatments in in vitro models and metastatic melanoma 
tumours; 
 To define the molecular features characterizing the consensus subtypes through 
an integrative analysis of “multi-omics” data. 
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3 MATERIALS AND METHODS 
3.1 Data retrieval 
For this project we made extensive use of publicly available transcriptomic and 
genomic data collected from different sources. For TCGA samples, all genomic data, but 
somatic mutations, were downloaded from the Broad Institute Firehose web portal 
(https://gdac.broadinstitute.org/, data version 2016_01_28). Somatic mutation data, 
obtained with the MuTect2 pipeline, where downloaded from the TCGA data repository 
(https://portal.gdc.cancer.gov/, accession date 10/04/2018). Clinical data were 
downloaded from the TCGA Pan-Cancer Atlas initiative (https://gdc.cancer.gov/about-
data/publications/pancanatlas, accession date 09/07/2018) and updated survival were 
obtained from supplementary table S1 of Liu et al (Liu et al., 2018). For meta-analysis of 
melanoma subtypes raw microarray data from melanoma clinical specimens and cell lines 
were retrieved from the NCBI Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) or EBI ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) databases. Downloaded datasets are listed in 
Table 3.1. For the in vitro model of melanocyte differentiation (Mica et al., 2013) 
normalized expression data were retrieved from GEO as well, with accession number 
GSE45227. Fragment Per Kilobase Million (FPKM) values for treated patients profiled in 
the studies of Hugo et al (Hugo et al., 2015; Hugo et al., 2016) were obtained from 
GSE65185 and GSE78220. For treated patients included in the study of Rizos et al (Rizos et 
al., 2014) raw gene expression data were downloaded from GSE50509. For treated 
patients in the study of Kwong et al (Kwong et al., 2015), aligned bam files were 
downloaded from the European Genome-phenome Archive repository 
(https://www.ebi.ac.uk/ega/home) with accession number EGAD00001001306. For cell 
lines of the Cancer Cell Line Encyclopedia (Barretina et al., 2012), mutational data were 
downloaded from the CCLE portal (https://portals.broadinstitute.org/ccle/data). 
Pharmacogenomic data from the Cancer Therapeutics Response Portal (CTRP) version 2 
(Seashore-Ludlow et al., 2015) were downloaded from the Cancer Target Discovery and 
Development data portal (https://ocg.cancer.gov/programs/ctd2/data-portal). 
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Table 3.1. List of public gene expression datasets of melanoma cell lines and clinical tumours used for 
consensus subtypes analysis. *: number of samples selected for analysis; †: obtained from the authors. 
 
3.2 Gene expression data preprocessing  
3.2.1 TCGA-SKCM 
TCGA RNA-Seq RSEM estimated raw counts were processed using the voom 
pipeline from limma (Law et al., 2014). The count matrix was normalized using the 
Trimmed Mean of M-values (TMM) method (Robinson and Oshlack, 2010), implemented 
in the edgeR package (Robinson et al., 2010). TMM estimates a scaling factor used to 
reduce technical bias between samples due to differences in library size. Normalized data 
were transformed in log2 counts per million (cpm) using the limma voom function. Entrez 
gene IDs were converted in HUGO gene symbols using NCBI annotation 
(ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/GENE_INFO/Mammalia/Homo_sapiens.gene_info, 
accession date 03/04/2018). The final dataset included 20413 unique genes and 471 
samples divided in 368 metastatic melanomas and 103 primary tumours. 
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3.2.2 Melanoma Clinical Samples from Microarrays dataset 
The Melanoma Clinical Samples from Microarrays (MCSM) dataset was assembled 
from 15 microarray studies obtained with Affymetrix or Illumina platforms. For each 
dataset raw data were normalized independently, with appropriate methods for each 
platform. Affymetrix gene arrays were pre-processed using the frozen robust multi-array 
average method (frma) (McCall et al., 2010). Affymetrix exon array were pre-processed 
using the robust multi-array average method (rma) (Irizarry et al., 2003). Illumina data 
were log2-transformed and normalized using the Robust Spline Normalization (RSN) 
method implemented in the lumi package (Du et al., 2008). After normalization, each 
dataset was annotated using Bioconductor annotation packages specific for each 
platform. Each normalized and annotated dataset was collapsed from probe- to gene-
level using the collapseRows (Miller et al., 2011) function of the WGCNA package 
(Langfelder and Horvath, 2008), selecting for each gene the probe with highest variation 
across samples. Technical replicates and samples obtained after treatment administration 
were removed before the pre-processing steps. The 15 datasets were then combined at 
the gene-level and ComBat (Johnson et al., 2007) was applied to remove batch effects. 
Data quality was assessed before and after ComBat correction evaluating the pair-wise 
sample distance calculated as 1- Pearson’s correlation coefficient. After quality control of 
batch-corrected data, 17 samples were identified as outliers (average correlation with all 
other samples < 0.7). These samples were removed from the uncorrected dataset then 
ComBat was newly applied. The final processed MCSM dataset consisted of 10332 unique 
genes and 897 samples. 
3.2.3 Melanoma Cell Lines dataset 
The datasets used to assemble the melanoma cell lines dataset were processed 
similarly to the MCSM dataset. In this case, all data were from Affymetrix Human Genome 
U133A-B or U133 Plus 2.0 platforms. Raw data were pre-processed using frma (McCall et 
al., 2010). Normalized datasets were merged at the probe-level considering only probe 
sets common among the different versions of the arrays. The merged dataset was 
collapsed to the gene-level using the collapseRows function (Miller et al., 2011) selecting 
for each gene the probe set with highest variation across samples. After data merging 
batch effects were removed using ComBat (Johnson et al., 2007). No outliers were 
detected after data quality control. The final dataset contained gene measurement for 
12992 unique genes and 504 samples representing 327 unique melanoma cell lines.  
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3.2.4 Anti-MAPK and anti-PD-1 targeted therapy datasets 
For GSE65185 and GSE78220 normalized FPKM values obtained by the authors of 
the respective publications were log2-transformed after adding a pseudo-count of 1. For 
GSE50509 raw Illumina microarray data were log2-transformed, normalized using the RSN 
method (Du et al., 2008) and collapsed at the gene-level using the collapseRows (Miller et 
al., 2011) function as described above. For EGAD00001001306 bam files were sorted by 
coordinates using samtools (Li et al., 2009) and raw gene-level counts were obtained 
using htseq-count (Anders et al., 2015) and Ensembl v75 GTF annotation file for hg19 
assembly. Count data were filtered removing genes with less than 1 cpm in all samples, 
normalized using TMM (Robinson and Oshlack, 2010) and transformed in log2-cpm using 
voom (Law et al., 2014). For all datasets only pre-treatment samples were considered for 
downstream analyses. 
3.3 Similarity analysis of published gene expression subtyping 
signatures 
The original gene expression signatures of Widmer et al (Widmer et al., 2012), Sensi 
et al (Sensi et al., 2011), Dugo et al (Dugo et al., 2015), Verfaillie et al (Verfaillie et al., 
2015), Rambow et al (Rambow et al., 2015), Tirosh et al (Tirosh et al., 2016), Jonsson et al 
(Jonsson et al., 2010) and Tsoi et al (Tsoi et al., 2018) were retrieved from the 
corresponding publications. The TCGA signature was downloaded from Broad Firehose 
data portal and each gene was assigned to the class with highest average expression 
according to the subtype assignments in the supplementary table 1D of the TCGA 
publication (The Cancer Genome Atlas Network, 2015). The pair-wise similarity of the 
gene content of the signatures was calculated using the Jaccard index that is a statistic 
used to evaluate the similarity between two categorical lists and is calculated as the ratio 
of the intersection and the union of the two lists. It ranges from 0 (no overlap) to 1 
(perfect overlap). The similarity at the pathway level was calculated in the same manner, 
using the lists of significantly enriched canonical pathways (Benjamini-Hochberg false 
discovery rate (Benjamini and Hochberg, 1995) (FDR) < 0.05) identified through the use of 
Ingenuity Pathway Analysis (IPA, QIAGEN Inc., https://www.qiagenbio-
informatics.com/products/ingenuity-pathway-analysis). 
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3.4 Identification of consensus melanoma subtypes 
Samples included in TCGA-SKCM, MCSM and MCL datasets were classified according 
to the nine gene expression-based signatures using the Nearest Template Prediction 
(NTP) algorithm (Hoshida, 2010) implemented in the GenePattern suite (Reich et al., 
2006). For each classifier samples with an NTP FDR < 0.25 were assigned to the 
corresponding subtype while the others were labeled as undetermined. The labels 
obtained from the nine classifiers were merged in a “samples x labels” matrix that was 
used to calculate the similarity between samples according to the Hamming distance. This 
kind of distance is the number of different subtype labels between two samples. If two 
samples are assigned to the same subtypes by the nine classifiers the Hamming distance 
is 0. If two samples have completely different subtypes assignments the Hamming 
distance is equal to the number of classifiers used, nine in this case. To identify a 
consensus of the multiple classifications we clustered the Hamming similarity matrix using 
consensus clustering (Monti et al., 2003) with the partition around medoids (PAM) 
algorithm, implemented in the ConsensusClusterPlus package (Wilkerson and Hayes, 
2010). Consensus clustering is a resampling technique that runs the same clustering 
algorithm for a specified number of iterations on a random subset of the data and then 
provides method to identify a consensus clustering across the multiple runs. The 
procedure was repeated for varying number of clusters K (K = 2 to K = 10). The optimal 
number of clusters was identified by examination of consensus matrices, the cumulative 
distribution function (CDF) plot and the delta area under the CDF (ΔCDF) plot. The 
consensus matrix reports the proportion of times in which two samples are clustered 
together across the resampling runs. The CDF plot shows the CDF of the consensus matrix 
values at each K. The K at which the CDF reaches a maximum is the number of clusters 
that gives the best separation of the data. The ΔCDF plot shows the relative change in 
area under the CDF curve between K and K-1 to determine at which K there is no 
appreciable increase in the consensus. 
The overlap between consensus clusters and labels from the nine classification 
systems was measured by Jaccard index and the statistical significance of the overlap was 
assessed by hypergeometric test. P-values were corrected for multiple testing using the 
Benjamini-Hochberg FDR (Benjamini and Hochberg, 1995). Only overlaps with Jaccard 
index ≥ 0.25 and FDR < 0.05 were considered significant and they were visualized through 
networks using Cytoscape v3.6.1. 
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3.5 Survival analysis 
Survival analysis was performed considering only stage III/IV metastatic melanoma 
patients from TCGA-SKCM dataset. Cox regression analysis, Kaplan-Meier curves and log-
rank test were performed using the survival R package. For univariate and multivariate 
Cox regression model the variables considered were consensus subtype and immune 
status according to CIBERSORT p-value. 
3.6 Analysis of pharmacogenomic data 
Consensus subtype labels for the 57 cell lines included in CCLE were extrapolated 
from the melanoma cell lines dataset. Association between consensus subtypes and drug 
sensitivity area under the fitted dose response curve (AUC) values was assessed using 
ANOVA followed by Tukey’s post hoc correction. A p < 0.05 after Tukey’s post hoc 
correction was set as significance threshold. Analysis was restricted to BRAFV600E mutant 
cell lines for selective BRAF inhibitors only. 
3.7 Analysis of treated patient’s datasets 
Gene expression data were analyzed using the moderated t-test implemented in 
the limma package to identify genes whose expression was positively or negatively 
associated to therapeutic response. For datasets including patients receiving BRAF 
targeted therapy (GSE50509, GSE65185 and EGAD00001001306) expression data were 
analyzed in association to best overall response, defined according to Response 
Evaluation Criteria In Solid Tumors (RECIST) criteria (Eisenhauer et al., 2009) as reported 
in the relative publications (Rizos et al., 2014; Hugo et al., 2015; Kwong et al., 2015). For 
the anti-PD-1 dataset (GSE78220) we compared the three response categories (complete 
response, partial response and progressive disease) in a pair-wise fashion. The classical 
limma pipeline was applied for Illumina microarray data of GSE50509. For 
EGAD00001001306 limma was applied after TMM normalization and voom 
transformation. For GSE65185 and GSE78220 we applied the classical limma pipeline to 
FPKM values, with the trend parameter of the eBayes function set to true. For each 
dataset Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) was performed 
on the list of genes ranked according to the t-statistics of limma. For GSEA, consensus 
subtypes gene sets were obtained from TCGA-SKCM dataset, selecting genes exclusively 
up-regulated in each subtype at an FDR < 0.05. Single-cell melanoma specific gene sets 
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were obtained from supplementary table 2D of Rambow et al (Rambow et al., 2018). 
HALLMARK gene sets were downloaded from MSigDB database (Liberzon et al., 2015). 
3.8 Molecular correlative analyses with consensus subtypes 
The molecular differences characterizing each consensus subtypes were 
investigated in TCGA-SKCM samples exploiting all multi-omics data available. Each 
platform was analyzed using specific methods detailed in the next sections. The 
comparisons were made comparing each subtype with the others in a one-versus-all 
fashion, unless otherwise specified. For all analyses p-values were adjusted for multiple 
comparisons using the Benjamini-Hochberg FDR. An FDR < 0.05 was considered 
statistically significant. Association between continuous numerical variables and 
consensus subtypes was statistically assessed by means of Analysis of Variance (ANOVA), 
followed by Tukey’s post-hoc test. Association between categorical variables and 
consensus subtypes was performed using Fisher’s exact test. 
3.8.1 Transcriptomics 
Differentially expressed genes were identified using the voom limma pipeline (Law 
et al., 2014). Pathways associated to each subtype were identified using the Gene Set 
Variation Analysis (GSVA) method implemented in the GSVA package (Hanzelmann et al., 
2013). This method estimates the enrichment of pathways for each single sample and 
enables the comparison of pathway enrichment scores across the samples of an 
expression dataset. For GSVA we used gene sets of the C5BP Gene Ontology (GO) 
biological process collection downloaded from the MSigDb database v6.1 (Liberzon et al., 
2011). The top-10% associated pathways in each subtype were then represented using 
the EnrichmentMap app (Merico et al., 2010) and Cytoscape v3.6.1. The EnrichmentMap 
algorithm generates a network connecting gene sets with genes in common. A threshold 
of 0.6 for the combined Jaccard and Overlap coefficients was applied to connect gene 
sets. The obtained network was manually curated to group clusters of gene sets in 
functional categories. Unconnected nodes were removed from the network. Additional 
custom gene sets were tested: Widmer and Verfaillie invasive/proliferative signatures 
(Widmer et al., 2012; Verfaillie et al., 2015), Sensi AXL+/- signatures (Sensi et al., 2011), 
Tirosh MITF/AXL signatures (Tirosh et al., 2016) and Tirosh cell type-specific genes (Tirosh 
et al., 2016). 
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 GSEA was performed on the list of genes pre-ranked according to the t-statistics 
obtained with limma. GSEA software was obtained from the Broad Institute website 
(http://software.broadinstitute.org/gsea/index.jsp). The cancer-testis antigens gene set 
was obtained from the Cancer-Testis database (CTdb, http://www.cta.lncc.br/) (Almeida 
et al., 2009). The chromosomal instability signature was obtained from Carter et al (Carter 
et al., 2006). 
Association between consensus subtypes and stages of melanocyte differentiation 
investigated in GSE45227 was calculated as follows: i) we selected the genes differentially 
expressed in at least one subtype; ii) for these genes we calculated the centroids (average 
expression) in each subtype of TCGA-SKCM and in each differentiation stage in GSE45227; 
iii) the Pearson’s correlation coefficient between TCGA-SKCM and GSE45227 centroids 
was calculated and the results were visualized through a heatmap. 
To evaluate the level of immune infiltration, stromal content and tumour purity 
we applied ESTIMATE (Yoshihara et al., 2013). This algorithm is based on single sample 
GSEA and uses an immune and a stromal signature to generate an immune and a stromal 
score. These two scores are then combined to obtain the estimate score from which 
tumour purity is derived. CIBERSORT (Newman et al., 2015) was applied to infer the 
immune cell composition of bulk tumours. CIBERSORT is a deconvolution method that 
quantifies the fraction of 22 immune cell subsets from gene expression data of bulk 
tumours. Samples with a significant deconvolution (CIBERSORT p-value < 0.05) were 
considered infiltrated by immune cells. This subset of samples was used to test the 
association between abundance of specific immune cells and consensus subtypes. 
3.8.2 Proteomics 
Differential protein expression analysis was performed using limma (Phipson et al., 
2016). Correlation between matched reverse-phase protein array (RPPA) and RNA-Seq 
data was calculated using the Pearson’s correlation coefficients. The distribution of the 
observed correlation coefficients was compared to a null distribution obtained by 
correlating proteins with random genes for 1000 iterations. 
3.8.3 MicroRNAs 
MicroRNA isoforms raw counts were preprocessed using the same voom/limma 
pipeline used for RNA-Seq data. Briefly, TMM was applied for between-samples 
normalization and normalized raw counts were transformed in log2-cpm. Differentially 
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expressed miRNAs were identified using limma after voom transformation. In silico 
prediction of miRNA targets was performed with six algorithms (DIANA MicroT-CDS 
(Reczko et al., 2012), microRNA.org database (Betel et al., 2008), mirDB (Wang, 2008), 
PITA (Kertesz et al., 2007), RNA22 (Miranda et al., 2006), and TargetScan v6.2 (Lewis et 
al., 2005)). Only targets predicted by at least two algorithms and negatively correlated 
with the miRNAs (Pearson’s correlation coefficient < -0.2) were selected. The biological 
function of each miRNA was inferred from the pathways significantly enriched in the list 
of its targets. Significantly enriched pathways were identified using the gProfileR package 
(Reimand et al., 2016) with GO biological process terms, KEGG and REACTOME pathways. 
We then calculated their similarity in terms of shared pathways using Jaccard index. This 
similarity matrix was clustered using hierarchical clustering with Euclidean distance and 
Ward linkage to find groups of miRNAs involved in similar biological pathways.  
3.8.4 DNA methylation 
DNA methylation data were obtained from Illumina Infinium 
HumanMethylation450 Array platform. The methylation level of each CpG site is 
calculated from the fluorescent signals of the methylated and unmethylated alleles 
through the β-value that is the ratio of the methylated probe and the sum of methylated 
and unmethylated probe intensities. β-values range from 0 (totally unmethylated) to 1 
(totally methylated). For statistical analyses β-values are converted to M-values that are 
the log2 ratio of the intensities of methylated probe versus unmethylated probe, while β-
values are used for visualization purposes. Level 3 β-values were filtered removing CpG 
probes with any missing value, CpG probes mapping on X and Y chromosomes and CpG 
probes located 1 or 2 nucleotides from known single-nucleotide polymorphism with a 
minimum minor allele frequency of 0.05. The overall methylation level of each sample 
was calculated by averaging the β-values of all CpG probes. For differential methylation 
analysis β-values were converted to M-values and differentially methylated sites were 
identified using the DMRcate package (Peters et al., 2015). The methylation level of each 
gene was calculated by averaging the M-values of the CpG probes mapping on the 
promoter region, identified using the annotatr package (Cavalcante and Sartor, 2017). 
Correlation between gene-level methylation data and RNA-Seq data was calculated using 
the Pearson’s correlation coefficient. The observed distribution of correlation coefficients 
was compared to a null distribution obtained by correlating methylation data with 
expression data from random genes for 1000 iterations. GSEA was performed on the list 
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of genes ranked according to their Pearson’s correlation coefficient between matched 
methylation and expression data using the fgsea package (Sergushichev, 2016) with GO 
biological process gene sets and consensus subtypes gene sets (genes up-regulated in 
each consensus subtype with a fold change > 3 and an FDR < 0.05). 
3.8.5 Somatic mutations 
Genomic subtypes were defined according to the mutational status of BRAF, 
(N/H/K) RAS and NF1 genes. Patients with BRAF mutation at V600 or K601 aminoacid 
residues were assigned to the BRAF hotspot mutant subtype. Patients with mutations at 
residues G12, G13, Q61 in (N/H/K) RAS were assigned to the RAS hotspot mutant subtype. 
Non-synonymous mutations in NF1 gene defined the NF1 mutant subtype. Remaining 
patients were assigned to the triple WT subtype. DeconstructSigs package (Rosenthal et 
al., 2016) was used to perform the mutational signature analysis. This tool evaluates the 
contribution of 30 signatures reported in COSMIC 
(https://cancer.sanger.ac.uk/cosmic/signatures) to the mutational profile of each sample. 
The obtained signature scores were then analyzed in association with consensus 
subtypes. The maftools package (Mayakonda and Koeffler, 2016) was used to parse 
mutational maf files. The number of mutations for each patient was calculated excluding 
synonymous ones. To identify non-synonymous mutations associated to consensus 
subtypes we defined a binary mutational state for each gene (0 if WT; 1 if any mutation) 
before performing Fisher’s exact test. 
3.8.6 Somatic copy number aberrations 
Tumour ploidy and purity estimated by ABSOLUTE algorithm (Carter et al., 2012) 
were downloaded from The Cancer Immunome Atlas database (https://tcia.at/) 
(Charoentong et al., 2017). Segmented copy number data were analyzed using GISTIC2.0 
(Mermel et al., 2011) to identify significantly recurrent somatic copy number aberrations 
across the entire TCGA-SKCM cohort, independently of consensus subtypes. Significant 
focal copy number alterations were then tested for association with consensus subtypes. 
For this analysis thresholded copy number data were used, considering amplifications and 
deletions separately. For amplifications, a gene was assigned a value of 1 if amplified or 0 
if the gene was WT. The same criteria were applied to deletions. The binary amplifications 
and deletions data were then used for the statistical analysis. GISTIC output was parsed 
using the maftools package (Mayakonda and Koeffler, 2016). The number of 
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amplifications and deletions per sample was calculated from the thresholded copy 
number data. Correlation between gene-level copy number and RNA-Seq data and GSEA 
were performed as described previously for methylation data. 
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4 RESULTS 
4.1 Melanoma classifiers and their overlap 
Nine gene expression-based melanoma classifications have been published and 
despite a concordance in the identification of two major groups defined by an invasive or 
a proliferative phenotype, discrepancies exist and a unified classification has not been 
derived yet. Before applying our bioinformatics approach to define a consensus 
classification, we evaluated the gene overlap of the nine gene expression signatures, 
reasoning that classifiers with a high number of shared genes would give concordant 
predictions. To measure the similarity of the selected signatures in terms of shared genes 
we calculated the Jaccard index between each pair-wise combination of signatures (36 
combinations in total). Results showed a poor overlap between classifiers with a 
maximum level of similarity of 0.25 between Widmer and Sensi signatures (Figure 4.1A). 
Due to the wide range of the number of genes included in the signatures (from 55 genes 
of Rambow to 1495 genes of TCGA) we did not expected high Jaccard values for gene lists 
with very different size. However, even for signatures of comparable size the overlap was 
still poor. 
We selected genes present in at least 5 signatures (> 50%) to identify a core set of 
recurring genes. No genes recurrent in all signatures were found. The most recurrent 
gene was MLANA, present in 8 out of 9 signatures, followed by DCT, GPR143, MITF and 
TYR, included in 7 signatures (Figure 4.1B). This core set of 30 genes was significantly 
enriched in targets of MITF according to IPA upstream regulators analysis (p = 1.55e-37), 
which are involved in the synthesis of melanin and in melanocyte development, 
suggesting that the most recurrent genes are representative of key biological processes in 
melanoma. Moreover, two different signatures with scarce overlap can represent 
different read-outs of the same biological process, thus we assessed the similarity among 
signatures in terms of biological function. The hypothesis is that reducing the 
heterogeneity among signatures shifting from a gene-level to a pathway-level the overlap 
of the signatures should increase. To this aim we performed over-representation analysis 
for each signature using IPA and we selected significantly enriched canonical pathways 
with an FDR < 0.05. We next evaluated the overlap of significantly enriched pathways 
between each pair of signatures (Figure 4.1C). Again, the number of significantly enriched 
pathways for each signature is highly variable, ranging from 1 for Tsoi and Tirosh to 167 
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for Verfaillie. The number of significantly enriched pathways is slightly correlated to the 
number of genes in each signature, despite not statistically significant (Figure 4.1D). Due 
to this heterogeneity a general increase in the Jaccard index values was not observed. 
Only four pair-wise combinations showed an increase of at least 0.1 when shifting from 
gene- to pathway-level (Jonsson-Dugo, Jonsson-TCGA, Dugo-Widmer and Sensi-Verfaillie). 
Four pathways were significantly enriched in at least 50% of signatures and included 
“hepatic fibrosis/hepatic stellate cell activation”, “WNT/β-catenin signaling”, “melanocyte 
development and pigmentation signaling” and “eumelanin biosynthesis” (Figure 4.1E). 
Overall, these results showed that the nine melanoma classifiers were very 
heterogeneous in terms of number and type of genes included and this heterogeneity 
was mirrored at the pathway-level. However, it was possible to identify a core of 
recurrent genes and pathways that converged on MITF transcriptional regulation. 
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Figure 4.1. Similarity of published melanoma gene expression signatures. A) Heatmap of Jaccard index 
values between each pair of signatures. The color intensity is proportional to the magnitude of Jaccard 
index, reported in each matrix cell. N: number of genes in the signature. B) Heatmap showing the genes 
recurring in at least 5 signatures. C) Heatmap of Jaccard index calculated from the number of enriched 
pathways in each signature. N: number of genes in the signature. D) Spearman correlation between the 
number of genes and the number of significantly enriched pathways in each signature. E) Heatmap of 
enriched pathways in at least 5 signatures. 
4.2 Identification of melanoma consensus molecular subtypes 
To explore how the different classifiers divided melanoma tumours and to identify a 
robust consensus classification we applied an analytical workflow to two transcriptomic 
datasets. The first dataset included 471 cutaneous melanomas profiled using RNA-Seq by 
the TCGA consortium (TCGA-SKCM). The second dataset was assembled from 15 public 
gene expression studies of melanoma tumours analyzed using Illumina or Affymetrix 
microarray platforms, for a total of 897 samples. For this dataset, hereafter called MCSM 
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(Melanoma Clinical Samples from Microarrays), raw data from each study were 
appropriately pre-processed and combined at the gene level using ComBat to correct for 
batch effects and reduce technical variation among studies. 
We assigned each sample of the two datasets to melanoma subtypes according to 
the nine classifiers using the NTP algorithm, a nearest neighbor-based class prediction 
method that provides the predicted class and a measure of significance of the assignment 
using only a list of signature genes. The percentage of samples assigned to a subtype by 
each classifier was comparable between TCGA-SKCM and MCSM datasets (Figure 4.2), 
confirming that both datasets are representative of melanoma phenotypic spectrum. 
Each signature was able to classify more than 80% of samples with the exception of 
Rambow and Tirosh classifiers that were characterized by a higher number of 
undetermined samples. The number of genes in Rambow classifier is very limited (n = 55) 
while Tirosh signature was derived from single-cell RNA-Seq data that are known to have 
a high level of technical noise in comparison to classical RNA-Seq or microarrays. These 
limitations could explain, at least in part, the reduced performance of the two classifiers. 
32 
 
 
Figure 4.2. Distribution of subtype labels in TCGA-SKCM and MCSM datasets. Bar plots showing the 
percentage of samples assigned to each subtype according to the nine published signatures. For each 
classifier, a sample was significantly assigned to a subtype if the NTP FDR was less than 0.25. Samples 
exceeding this threshold were labeled “undetermined”. 
After NTP classification we obtained for each sample nine subtype labels. The 
classifications of TCGA-SKCM and MCSM samples were then combined in a matrix 
containing the nine subtype labels for all 1368 samples. In this way, the labels that were 
obtained from each dataset separately could be merged without introducing noise or 
artifacts due to the technological differences between the two datasets. To identify a 
consensus classification we calculated the similarity between samples according to their 
labels using the Hamming distance that corresponds to the number of different labels 
between two samples. Samples were then clustered according to this distance measure 
using consensus clustering in combination with the PAM algorithm and varying number of 
clusters K (K = 2 to K = 10). To estimate the optimal number of clusters we visually 
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examined for each K the consensus matrices, the cumulative distribution function (CDF) 
plot and the delta area under the CDF (ΔCDF) plot. The consensus matrix is a symmetric 
matrix, where both rows and columns represent samples and collects the proportion of 
times in which two samples are clustered together across the resampling runs (n = 1000). 
The CDF plot shows the CDF of the consensus matrix values at each K allowing visualizing 
at which K the CDF reaches a maximum. The ΔCDF plot shows the relative change in area 
under the CDF curve between K and K-1 to determine at which K there is no appreciable 
increase in the consensus. Evaluation of these plots pointed out that the optimal number 
of cluster was 5 as there was no noticeable increase in area under CDF function after K = 5 
(Figure 4.3B-C) and the consensus matrix at K = 5 showed five well-separated blocks on 
the diagonal, even if clusters 4 and 5 showed a certain degree of overlap for some 
samples (Figure 4.3A). The same consensus analysis was repeated for TCGA-SKCM and 
MCSM independently (Figure 4.4). In both datasets we found that the optimal number of 
clusters was 5 reinforcing the reliability of the partitioning.  
 
Figure 4.3. Consensus PAM clustering subtypes using TCGA-SKCM and MCSM combined labels. A) 
Consensus matrices for k = 2 to k = 5. Rows and columns represent samples and consensus values range 
from 0 (never clustered together) to 1 (always clustered together) marked by white to dark blue. B) CDF 
plot shows the cumulative distribution functions of the consensus matrix for each k. At k = 5 the CDF 
reaches a maximum with negligible improvement at k > 5. C) The relative change in area under CDF curve 
shows that as k is increasing beyond 5, there is a significant drop in the relative change in area under CDF 
curve, indicating an optimum at k = 5. 
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Figure 4.4. Consensus PAM clustering subtypes using TCGA-SKCM (A-C) and MCSM (D-F) separately. A, D) 
Consensus matrices for k = 2 to k = 5. Rows and columns represent samples and consensus values range 
from 0 (never clustered together) to 1 (always clustered together) marked by white to dark blue. B, E) CDF 
plot shows the cumulative distribution functions of the consensus matrix for each k. At k = 5 the CDF 
reaches a maximum with negligible improvement at k > 5. C, F) The relative change in area under CDF curve 
shows that as k is increasing beyond 5, there is a significant drop in the relative change in area under CDF 
curve, indicating an optimum at k = 5. 
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We then measured the overlap of consensus labels identified by PAM clustering 
with tumour labels from the nine classification systems. The overlap was visualized 
through the use of a heatmap (Figure 4.5A). We also statistically assessed the overlap 
using Jaccard index and hypergeometric test. Significant overlaps (Jaccard index ≥ 0.25 
and hypergeometric FDR < 0.05) were displayed as a network (Figure 4.5B). CS2 and CS3 
were representative of invasive samples with CS2 being enriched of “ERBB3-LOW-
Invasive”, “Undifferentiated”, ”Immune” and “High-immune” subtypes and CS3 of 
“ERBB3-HI-Invasive”, “Neural crest-like”, “Proliferative” from Jonsson and “MITF-low”. 
Interestingly, CS2 was also enriched of “Undetermined” samples from Rambow signature. 
This observation suggested that this signature, containing only 55 genes, did not 
recognize these samples as classical invasive, supporting the splitting of the invasive 
subtype in two sub-groups. In the same way, CS1 and CS4 both included proliferative 
samples but CS1 was enriched of “ERBB3-HI-Proliferative”,”MITF-program”,”Keratin” and 
“Pigmentation” while CS4 consisted of “Transitory” samples. Finally, CS5 was enriched in 
samples classified as “Undetermined” by the majority of signatures, indicating the 
existence of a fifth group that could not be discriminated by the actual classifiers. 
Overall, these results showed that melanoma tumours can be classified in five 
robust subtypes, with four of them corresponding to previously described biological 
entities. In addition, a new subtype that comprises samples classified as “Undetermined” 
by the nine classification systems was discovered. This last subtype could represent a new 
biological subset of melanomas not previously identified. 
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Figure 4.5. Comparison of consensus subtypes and the original classification systems. A) Overlap between 
consensus subtypes (CS1-CS5) and labels assigned by the nine melanoma gene classifiers for the combined 
TCGA-SKCM and MCSM datasets. B) Association of consensus subtypes with subtype labels from the 9 
classification systems. Each node is a subtype label (circular node are consensus subtypes) colored 
according to the color scheme in A). Edge width is proportional to the overlap between labels measured 
using Jaccard index. Only significant overlaps (hypergeometric FDR < 0.05) are shown. 
4.3 Differential pathway activation of consensus molecular subtypes 
4.3.1 Transcriptomics 
To assess transcriptional differences among subtypes on a pathway-based level 
we applied GSVA to TCGA-SKCM dataset, comparing each subtype with the others. We 
first focused on the previously reported invasive/proliferative gene signatures (Figure 
4.6A). As expected, CS2 and CS3 subtypes showed a strong up-regulation of invasive 
signatures and were depleted for proliferative ones. Vice versa, CS4 and CS1 groups 
showed an opposite enrichment pattern. These results confirmed that these four 
subtypes were a further subdivision of the two major invasive and proliferative 
phenotypes, as already demonstrated in previous works (Dugo et al., 2015; Tsoi et al., 
2018). Interestingly, the CS5 subtypes showed a negative enrichment of both invasive and 
proliferative signatures. Investigation of the expression pattern of single genes relevant 
for melanoma biology and classification confirmed this finding. MITF and its target genes 
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MLANA and PMEL were expressed at lower levels in CS2 and CS3 subtypes while they 
were up-regulated in CS4 and CS1 (Figure 4.6B). The opposite pattern was observed for 
the receptor tyrosine kinases AXL and EGFR. Also SOX10, a major regulator of neural crest 
development, was down-regulated in the CS2 subtype in comparison to the CS4 and CS1 
proliferative groups. For all these genes CS5 subtype showed an intermediate level of 
expression. These observations indicated that CS5 subtype could be a turning point 
between invasive and proliferative phenotypes, preceding the CS4 subtype along the 
melanocyte differentiation process. 
 
Figure 4.6. Phenotype switching and differentiation features of consensus subtypes. A) GSVA analysis for 
invasive and proliferative gene sets. The heatmap shows the log fold change of the normalized enrichment 
scores obtained comparing each subtypes versus the others. An “X” denotes that the FDR associated to the 
fold change is not significant (FDR ≥ 0.05). B) Box plots of expression levels for selected relevant genes 
involved in phenotype switching. A “+” or a “-“ indicate that the gene is significantly up- or down-regulated, 
respectively. C) Heatmap of the Pearson’s correlation coefficient between the centroids of consensus 
subtypes and of experimental conditions of the melanocyte differentiation in vitro model from GSE45227. 
To confirm this hypothesis we compared subtypes with a gene expression dataset 
recapitulating an in vitro model of human melanocyte differentiation (GSE45227, (Mica et 
al., 2013). This dataset consisted of a time-course experiment of human embryonic stem 
cells (ESC) sequentially treated to induce differentiation to neural crest cells, 
melanoblasts and mature melanocytes. Tsoi et al (Tsoi et al., 2018) already compared 
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their melanoma subtypes with the melanocyte differentiation stages using this same 
dataset. However, they considered for the comparison only selected time points 
representative of the major differentiation states but excluded all other time points that 
could represent intermediate states. Here we performed a more detailed analysis 
comparing the five consensus subtypes with all time points available. To this aim we 
calculated for the five consensus subtypes identified in TCGA-SKCM dataset the centroid, 
i. e. the mean expression profile of samples within the same subtype. For this calculation 
we considered only the genes that were significantly differentially expressed in at least 
one subtype (ANOVA FDR < 0.05). Using the same subset of genes we next calculated the 
centroids of each time point in the differentiation dataset. Finally, we calculated the 
correlation between the centroids of the two datasets. The CS2 subtype correlated well 
with ESC stage, while CS1 resembled the mature melanocytes phenotype, with the CS3 
and CS4 representing the intermediate stages of neural crest and melanoblast, 
respectively. As hypothesized, the CS5 located in between the CS3 and CS4 subtypes, 
representing a late neural crest/early melanoblast stage (Figure 4.6C). 
To gain a broader overview of the biology underlying each specific subtype we 
repeated GSVA for each group compared with the remaining four using the Gene 
Ontology (GO) terms of the biological process domain. We identified several significantly 
enriched pathways for each subtype, supporting subtype-specific transcriptional 
alterations. The top-100 GO terms significantly enriched in each subtype (FDR < 0.05) 
were visualized as a network to identify clusters of overlapping gene sets attributable to 
the same biological process (Figure 4.7). In CS2 we observed an enrichment of genes 
involved in several signaling pathways such as RTK, PIK3CA, MAPK and JAK/STAT signaling 
and in immune system. Angiogenesis, cellular migration, extracellular matrix remodeling 
and neural crest differentiation were enriched in the CS3 subtype. In the two proliferative 
subtypes (CS4 and CS1) we found enrichment of gene sets related to pigment cell 
differentiation and pigment biosynthesis but CS4 was specifically enriched of genes 
involved in transcription, mRNA processing and splicing, DNA repair and DNA 
methylation. On the other side CS1 was preferentially enriched of metabolic gene sets. 
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Figure 4.7. Subtype-enriched pathways. Network showing the top-10% GO biological process terms in each 
subtype. Each node is a GO term and node size is proportional to the number of its genes. Nodes with genes 
in common are connected by an edge whose width is proportional to the number of shared genes. Nodes 
are colored according to the subtype in which they are enriched; multiple colors indicate that the gene set 
is enriched in more than one subtype. Cluster of nodes sharing several genes were manually grouped in 
biological macro-categories. 
The newly discovered CS5 subtype showed up-regulation of genes involved in 
ribosome assembly, chromatin remodeling and meiosis. Many regulators of meiosis are 
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expressed in germ cells and are silenced in healthy somatic tissues but they can be 
aberrantly expressed in cancerous tissues inducing chromosomal instability (CIN). These 
genes are referred as cancer-testis antigens (CTAs) and they are frequently expressed in 
melanoma. Given these premises we hypothesized that the CS5 subtype could be 
characterized by over-expression of CTAs and high CIN. Our hypothesis was confirmed by 
GSEA analysis that highlighted the strong positive enrichment of CTAs and of a CIN 
signature (Carter et al., 2006) in the genes up-regulated in this subtype (Figure 4.8A-B). 
Overall, these results confirmed that the consensus subtypes recapitulated the 
differentiation stages from ESC to fully differentiated melanocytes and each subtype was 
characterized by the activation of specific pathways. To give the consensus subtypes more 
meaningful names we adopted the nomenclature already used in the work of Tsoi et al 
except for CS4 and the newly discovered CS5 (Table 4.1). Having shown that CS5 was the 
true intermediate state between the two invasive and proliferative subtypes, and it was 
characterized by high CIN, we named the CS5 subtype as “Transitory/CIN”. The CS4 
subtype that was the original transitory subtype from Tsoi et al (Tsoi et al., 2018) was 
renamed “Melanoblast-like”, as our analyses showed that it corresponded to cells in the 
state of melanoblast along the differentiation axis. 
 
Table 4.1. Nomenclature of melanoma consensus subtypes. 
Consensus subtype Name 
CS2 Undifferentiated 
CS3 Neural crest-like 
CS5 Transitory/CIN 
CS4 Melanoblast-like 
CS1 Melanocytic 
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Figure 4.8. Enrichment of CTAs and CIN signatures in consensus subtypes The plots show the enrichment 
of CTA (A) and CIN (B) gene sets in each subtype. The grey bar plot at the bottom of each plot shows the 
genes ranked from the most up-regulated (right) to the most down-regulated (left) in each subtype. The 
vertical black bars show where the genes of the gene sets fall along the ranked gene list, together with the 
running enrichment score (green line). For each analysis the enrichment score (ES), normalized enrichment 
score (NES), p-value and FDR are reported.  
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4.3.2 Correlation between mRNA and protein levels 
Reverse-phase protein array (RPPA) is a high-throughput proteomic technology 
that uses antibody binding to quantify protein expression. For a subset of 353 samples of 
TCGA-SKCM cohort both RNA-Seq and RPPA data were available. RPPA expression 
measurements were available for 156 total proteins and all of them had matched mRNA 
data. We first assessed to what extent protein expression levels correlated with their 
mRNA expression. Overall, we found that Pearson’s correlation coefficients for matched 
proteins and genes were shifted toward positive values (median = 0.24) compared to the 
null distribution of the correlation coefficients (median = 0) calculated using random 
matching of protein and RNA-Seq data for 1000 iterations (Figure 4.9A). This observation 
indicated that protein and corresponding mRNA levels were generally well correlated 
supporting the functional effect of the alterations observed at the gene expression level. 
We next investigated the association between protein expression and consensus 
subtypes. For each subtype compared with all other four we found several proteins 
significantly differentially expressed (Figure 4.9B). 
 
Figure 4.9. Analysis of TCGA-SKCM proteomic data. A) Distribution of the actual Pearson’s correlation 
coefficients between each protein and its corresponding gene (green curve) compared to a random null 
distribution calculated by permuting genes 1000 times (red curve). Vertical lines represent the medians of 
the distributions. B) Number of significantly up-regulated (red) and down-regulated (blue) proteins (FDR < 
0.05) for each subtype versus the others. 
The undifferentiated subtype showed higher expression of Axl and reduced 
expression of Her3 as already observed at the mRNA level (Figure 4.10). Among the most 
up-regulated proteins in undifferentiated samples, we found markers of invasiveness such 
as Annexin-I, Annexin-VII and Caveolin-1. In addition, Syk and Lck, two proteins 
representative of T- and B-cell signaling, were highly up-regulated, confirming the high 
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prevalence of immune infiltrated tumours in this subtype. The neural crest-like subtype 
showed the same modulation pattern of the molecules described above for the 
undifferentiated group, confirming the invasive phenotype of these two subtypes. In 
addition, neural crest-like tumours showed up-regulation of additional markers of 
angiogenesis (IGFBP2) and invasiveness such as fibronectin, the integrin CD49b and PKC-
alpha, in concert with loss of E-cadherin expression. We also found up-regulation of 
asparagine synthetase (ASNS) in this specific subtype. The two proliferative subtypes 
showed an opposite expression patterns for the proteins described above, more markedly 
in the melanocytic subtype. Compared to melanoblast-like tumours, the melanocytic 
subtype showed a higher expression of mTOR, Akt, E-cadherin and proliferation markers 
such as PCNA, Cyclin-E1 and Cyclin-B1. The melanoblast-like subtype showed specific up-
regulation of STAT5-alpha, eEF2K and Her2. Finally the transitory/CIN subtype showed up-
regulation of several DNA repair proteins such as MSH6, RBM15, GAB2 and Bim. 
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Figure 4.10. Heatmap of log fold changes for selected significant proteins. Yellow cells represent proteins 
not differentially expressed in the given subtype. The heatmap on the right shows the Pearson’s correlation 
coefficient between the protein and the respective gene. 
4.4 Microenvironment of consensus subtypes 
The enrichment of immune-related gene sets in the undifferentiated subtypes 
made us hypothesize that consensus subtypes could be characterized by different tumour 
microenvironments. We applied ESTIMATE, a method that uses specific stromal and 
immune signatures to infer from gene expression data the fraction of stromal and 
immune cells in a bulk tumour sample. Stromal and immune scores are then combined to 
finally derive the sample tumour purity. Undifferentiated samples showed the highest 
immune score compared to all other (Figure 4.11A). The stromal score was highest in the 
undifferentiated subtypes but also neural crest showed a higher enrichment of stroma 
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compared to transitory/CIN, melanoblast-like and melanocytic (Figure 4.11B). 
Consequently, undifferentiated and neural crest-like samples were characterized by lower 
tumour purity (Figure 4.11C). To deeper investigate the microenvironment composition 
of consensus subtypes we performed GSVA using a set of cell-type specific signatures 
derived from a single-cell RNA-Seq study of melanoma samples (Tirosh et al., 2016). The 
results confirmed that undifferentiated samples were highly enriched in stromal and 
immune cells, including macrophages, B cells, endothelial cells and fibroblasts (Figure 
4.11D). The neural crest-like subtype showed a positive enrichment of fibroblasts and 
endothelial cells, even if to a less extent, while it did not show enrichment of B cells. 
Oppositely, the two proliferative subtypes were enriched of melanocyte markers and 
showed a negative enrichment of stromal populations. The transitory/CIN subtype was 
not infiltrated by immune cells but was also negatively enriched of melanocyte markers, 
reinforcing the hypothesis that this subtype consisted of tumour cells in an intermediate 
state between invasive and proliferative phenotypes. 
 
Figure 4.11. Microenvironment contribution to the gene expression of consensus subtypes. A-B) Box plot 
of the stromal and immune score calculated from the expression of specific markers using the ESTIMATE 
package. C) Tumour purity inferred from the combination of the stromal and immune score. P-values were 
obtained with ANOVA followed by Tukey’s post hoc test. ***: p < 0.001; **: p< 0.01; *: p< 0.05. D) Heatmap 
of the average NES calculated using GSVA for cell-specific markers in each subtype.  
To quantify the immune cellular composition of consensus subtypes we next 
applied CIBERSORT, a gene expression deconvolution method that can estimate the 
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relative proportion of 22 immune cell populations in bulk tumour samples. In addition to 
the estimated cell fractions, CIBERSORT returns a p-value of the deconvolution. This p-
value tests the null hypothesis that none of the immune cells assessed by the algorithm 
are present in a given sample. Thus, samples with a significant deconvolution (p < 0.05) 
were considered “immune” while remaining samples were classified “non-immune”. 
Association with consensus subtypes revealed that the majority of immune samples 
belonged to the undifferentiated subtype (χ2 p-value = 5.6e-22) (Figure 4.12A). 
Considering only samples with a significant CIBERSORT p-value, we evaluated the 
differential abundance of immune cell populations across consensus subtypes. Among the 
22 subpopulations tested, 3 were significantly (ANOVA p < 0.05) differentially represented 
in the different subtypes (Figure 4.12B-D). The most significant difference in 
subpopulation content was observed between undifferentiated and neural crest-like 
subtype with macrophages M0 abundance and CD8+ T cells being lower and higher in the 
first subtype, respectively. Other significant differences were in both M0 and M2 
macrophages among undifferentiated and melanocytic subtype.  
 
Figure 4.12. Association between immune infiltration status defined by CIBERSORT and consensus 
subtypes. The percentage of immune samples (CIBERSORT p-value < 0.05, dark grey) and non-immune 
samples (CIBERSORT p-value ≥ 0.05, light grey) are presented for each subtype. B-D) Box plots of 
CIBERSORT-inferred cell proportions for the cell subpopulations with an ANOVA p-value < 0.05. Reported p-
values for pair-wise comparisons were calculated using Tukey’s post-hoc test. 
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4.5 Prognostic impact of consensus subtypes 
Identification of prognostic molecular biomarkers to improve the stratification of 
patients in different risk categories is a hot topic of research in oncology. In melanoma, 
patients with primary tumours can reach high rate of survival depending on stage at 
diagnosis while survival of patients with metastatic disease is poor. However, long 
survivors among patients with advanced disease can be observed, indicating that clinically 
approved prognostic biomarkers alone do not explain the observed variability in 
outcome. Here we assessed the prognostic impact of consensus subtypes in relation to 
overall survival for 161 TCGA-SKCM patients with stage III-IV metastatic disease. 
According to univariate Cox proportional hazards analysis, patients within the 
melanocytic and transitory/CIN subtype had an increased risk of death compared to all 
other groups (Figure 4.13A and Table 4.2). Neural crest-like patients had the best 
prognosis compared to all other subtypes. Based on previous findings reporting a 
protective role of immune infiltration for melanoma patients we categorized TCGA-SKCM 
samples in “Immune” or “Non-immune” according to the significance (p < 0.05) of the 
CIBERSORT p-value. Patients belonging to the immune class had significantly higher 
survival rates compared to the non-immune class (Table 4.2 and Figure 4.13B). We next 
performed a multivariate Cox regression analysis to simultaneously assess the influence 
of consensus subtypes and immune status on overall survival. The two variables 
maintained their association with overall survival suggesting that consensus subtype and 
immune status jointly impact on survival (Table 4.2). 
 
Figure 4.13. Prognostic impact of consensus subtypes and immune infiltration in stage III-IV metastatic 
melanoma of TCGA-SKCM dataset. A-B) Kaplan-Meier curves based on consensus subtypes (A) and immune 
status defined by CIBERSORT p-value (B). P-values were obtained through the log-rank test. 
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Table 4.2. Univariate and multivariate Cox regression analysis for consensus subtypes and immune status 
in metastatic patients of TCGA-SKCM dataset. Significant p-values are highlighted in bold. N: total number 
of samples; HR: hazard ratio; CI: confidence interval. 
  Univariate analysis Multivariate analysis 
Variable Events/N HR 95% CI p HR 95% CI p-value 
 
Consensus subtype 
Melanocytic 
Melanoblast-like 
Transitory/CIN 
Neural crest-like 
Undifferentiated 
 
 
 
29/49 
14/30 
9/14 
12/30 
14/38 
 
 
1 
0.52 
1.02 
0.36 
0.47 
 
 
Ref 
0.27-1.01 
0.48-2.17 
0.18-0.71 
0.25-0.91 
 
 
Ref 
0.053 
0.951 
0.003 
0.026 
 
 
1 
0.59 
1.06 
0.45 
0.53 
 
 
Ref 
0.30-1.17 
0.49-2.25 
0.22-0.89 
0.25-1.10 
 
 
Ref 
0.130 
0.889 
0.023 
0.087 
Immune status 
Non-immune 
Immune 
 
 
49/88 
29/73 
 
1 
0.53 
 
Ref 
0.33-0.85 
 
Ref 
0.009 
 
1 
0.53 
 
Ref 
0.31-0.91 
 
Ref 
0.020 
 
4.6 Identification of consensus subtypes in melanoma cell lines 
Tumour-derived cell lines are the most common models used in cancer research to 
study the molecular mechanisms of cancer and response to drugs. Understanding how 
closely cell lines resemble in vivo tumours is crucial to evaluate the clinical significance of 
discoveries made using in vitro models. To this aim we applied the same unsupervised 
consensus PAM clustering approach used to identify the consensus subtypes in bulk 
melanoma tumours to a large gene expression dataset of melanoma cell lines. We opted 
to apply the unsupervised PAM approach, instead of deriving a predictor of the consensus 
subtypes from bulk tumour data, to avoid possible confounding in gene expression signals 
related to tumour microenvironment components. 
As for bulk tumours, we first classified each cell line using the nine published 
signatures and then we applied consensus PAM clustering on the matrix of subtype 
labels. Inspection of the consensus matrices, area under the CDF curve and ΔCDF plot 
showed that the optimal number of clusters was 5 (Figure 4.14). This was in agreement 
with what was observed on TCGA-SKCM and MCSM datasets. 
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Figure 4.14. Identification of consensus subtypes through consensus PAM clustering in melanoma cell 
lines. A) Consensus matrices for k = 2 to k = 5. Rows and columns represent samples and consensus values 
range from 0 (never clustered together) to 1 (always clustered together) marked by white to dark blue. B) 
CDF plot shows the cumulative distribution functions of the consensus matrix for each k. At k = 5 the CDF 
reaches a maximum with negligible improvement at k > 5. C) The relative change in area under CDF curve 
shows that as k is increasing beyond 5, there is a significant drop in the relative change in area under CDF 
curve, indicating an optimum at k = 5. 
We next verified whether the 5 subtypes identified in cell lines corresponded to 
the consensus subtypes from clinical specimens. The same pattern of overlap between 
the consensus classification and the labels from the nine published classifiers was 
observed (Figure 4.15A). CS2 included the subset of invasive cell lines classified as ERBB3-
LOW-Invasive or undifferentiated by Dugo and Tsoi classifiers, respectively. The CS2 
subtype was also enriched of cell lines classified as High-immune and Immune by Jonsson 
and TCGA. This suggested that the expression of immune-related genes was a tumour-
intrinsic trait and it was not uniquely related to the infiltration of immune cells in bulk 
tumours. The second subset of invasive cell lines was enriched in the CS3 subtype. The 
CS4 and CS5 groups were enriched of transitory proliferative and keratin/melanocytic cell 
lines, respectively. Finally, the newly identified CS5 was present also in cell lines and 
grouped the majority of samples that were classified as undetermined by the nine 
predictors. As observed for clinical tumours, the 5 consensus subtypes identified in vitro 
recapitulated the different stages of melanocytes differentiation (Figure 4.15B). Finally, 
consensus subtypes signatures previously identified in TCGA-SKCM dataset were tested 
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for enrichment in the 5 five in vitro consensus subtypes. We observed that each signature 
was positively enriched in its correspondent in vitro subtype, with the exception of the 
melanocytic signature that was enriched in both CS1 and CS5 (Figure 4.15C). Collectively, 
these results showed that consensus subtypes and their expression patterns were 
consistent between bulk tumours and in vitro cell lines. 
 
Figure 4.15. Similarity between in vitro and in vivo consensus subtypes. A) Heatmap showing the overlap 
between consensus subtypes and subtype labels assigned by the 9 melanoma gene signatures. B) Heatmap 
of the Pearson’s correlation coefficient between the centroids of consensus subtypes and of experimental 
conditions of the melanocyte differentiation in vitro model from GSE45227. C) Enrichment of consensus 
subtype-specific signature derived from clinical tumours in the cell lines consensus subtypes. 
4.7 Consensus subtypes and in vitro drug sensitivity 
To link our consensus subtypes to drug sensitivity we analyzed gene expression data 
for the subset of 57 melanoma cell lines included in CCLE and matched pharmacological 
profiles for 481 drugs available from CTRP pharmacogenomic database. We and others 
previously showed that the invasive and proliferative phenotypes determined sensitivity 
to BRAF inhibitors with the first being intrinsically resistant to the drug and the latter 
being more sensitive (Konieczkowski et al., 2014; Muller et al., 2014; Dugo et al., 2015). 
We tested the response to BRAF inhibitors in the context of our new consensus 
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classification system, considering only 38 cell lines harboring the BRAFV600E mutation. The 
same pattern of sensitivity across subtypes was observed for all four BRAF inhibitors 
tested (Figure 4.16). Undifferentiated cell lines were the most intrinsically resistant 
compared to all other groups. Interestingly, between the two proliferative subtypes the 
melanoblast-like was more sensitive compared to the melanocytic. The only cell line 
tested for the transitory/CIN subtype showed high sensitivity but unfortunately, we could 
not draw robust conclusions due to limited sample size.  
 
Figure 4.16. Subtype-specific sensitivity to BRAF inhibitors. Association between area under the curve 
(AUC) values for the four BRAF inhibitors available in CTRP database and consensus subtypes for CCLE cell 
lines. Higher AUC values are associated lower sensitivity. The horizontal black bars represent the median 
AUC value for each subtype. Not all cell lines were tested for all drugs. 
Beyond BRAF inhibitors, we assessed the sensitivity level of our consensus 
subtypes to all other drugs tested, for all 57 cell lines irrespectively of BRAF mutations. 
This analysis was aimed to identify alternative drugs for BRAF inhibitor-refractory cells but 
also subtype-specific effective treatments for cell lines lacking the BRAFV600E mutation. We 
compared the drug profiles of consensus subtypes in a pair-wise fashion and we selected 
49 drugs with subtype-specific sensitivity (Tukey’s post hoc p-value < 0.05 in at least one 
contrast). The pattern of sensitivity for these drugs was represented through a heatmap 
to identify the most effective drugs for each subtype (Figure 4.17A). The undifferentiated 
subtype was characterized by higher sensitivity to ferroptosis-inducing drugs such as 
ML210, ML162, erastin and 1S,3R-RSL-3, as already described (Tsoi et al., 2018). In 
addition, undifferentiated cell lines were more sensitive to dasatinib (SRC inhibitor), 
axitinib and Ki8751 (inhibitors of VEGFRs, c-KIT, and PDGFRs), SGX-523 (MET inhibitor), 
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NVP-TAE684 (ALK inhibitor) and CHIR-99021 (GSK3B inhibitor). The ROS-inducer BRD-
K71935468, marinopyrrole A (putative inhibitor of MCL1), pifithrin-alpha (inhibitor of p53-
dependent signaling) and RO4929097 (inhibitor of gamma-secretase) were more effective 
in neural crest-like cell lines. The melanocytic subtype showed higher sensitivity to several 
drugs belonging to the family of the histone deacetylase (HDAC) inhibitors and to the p38-
MAPK inhibitor skepinone-L. On the other side, melanoblast-like cell lines showed higher 
sensitivity to several drugs including inhibitors of MEK1 and MEK2 (PD318088, 
selumetinib and trametinib) and proteasome inhibitors (MG-132 and bortezomib). The 
novel transitory/CIN subtypes showed specific sensitivity to the BIRC5 inhibitor YM-155 
and to the inhibitor of PLK1 BI-2536 (Figure 4.17B) whose targets are up-regulated in this 
subtype (Figure 4.17C).  
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Figure 4.17. Association between drug response profiles and consensus subtypes. A) Heatmap of AUC 
values for CTRP drugs significantly associated to consensus subtypes. The colored bar on top delineates the 
consensus subtype. The vertical colored bar on the left indicates in which consensus subtype a drug is more 
effective. B) Plot showing the AUC values for the two drugs more effective in the transitory/CIN subtype. C) 
Box plot of the expression levels of the targets of the drugs represented in B). Box plot were obtained 
considering all 504 cell lines of the melanoma cell line dataset. Fold change (FC) and FDR refer to the 
contrast between transitory/CIN subtype and the others. 
4.8 Predictive role of consensus subtypes in clinical tumours 
To evaluate to which extent the role of consensus subtypes as predictive biomarker 
could be translated from an in vitro to an in vivo setting, we evaluated three gene 
expression datasets of BRAF-mutated metastatic melanoma patients treated with MAPK 
inhibitors (Rizos et al., 2014; Hugo et al., 2015; Kwong et al., 2015). Additionally, we 
evaluated the ability of consensus subtypes to predict response to immunotherapy in a 
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dataset of metastatic melanoma patients treated with the PD-1 inhibitor pembrolizumab 
(Hugo et al., 2016). For these analyses we focused on the prediction of intrinsic 
resistance, thus only pre-treatment samples were considered (Table 4.3). 
 
Table 4.3. Gene expression datasets of metastatic melanoma patients treated with targeted- or immuno- 
therapy. Summary of datasets composition. N: number of pre-treatment patients; Dab: dabrafenib; Vem: 
vemurafenib; Tra: trametinib. 
Dataset (N) Sex Age 
(Years) 
Treatment BRAF 
Mutation 
Metastatic 
site 
GSE50509 (21) 
M (14) 
F (7) 
54 ± 18 
Dab (16) 
Vem (5) 
V600E (14) 
V600K (6) 
V600R (1) 
Subcutaneous 
(14) 
Lymph node 
(3) 
Brain (4) 
GSE65185 (18) 
M (13) 
F (5) 
58 ± 13 
 
Dab (1) 
Vem (12) 
Dab+Tra (4) 
Vem+GDC0973 (1) 
V600E (13) 
V600K (4) 
V600R (1) 
Cutaneous (7) 
Subcutaneous 
(9) 
Lymph node 
(1) 
Breast (1) 
EGAD00001001306 
(14) 
NA 51 ± 17 
Vem (3) 
Dab + Tra (11) 
V600E (14) NA* 
GSE78220 (26) 
M (18) 
F (8) 
61 ± 13 
Pembrolizumab§ 
(26) 
V600E (8) 
V600K (2) 
V600R (1) 
WT (13) 
Subcutaneous 
(14) 
Lymph node 
(2) 
Other (10) 
 
For patients treated with anti-MAPK therapy, we applied GSEA to correlate the 
expression of the consensus subtype-specific signatures to the best overall response 
evaluated according to RECIST criteria (Eisenhauer et al., 2009). For the anti-PD-1 dataset, 
consensus subtypes signatures were evaluated in association to the classification of 
patients in complete response (CR), partial response (PR) or progressive disease (PD). We 
found an inconsistent pattern of enrichment among datasets. The undifferentiated 
signature was positively enriched in patients with the strongest disease reduction in 
GSE50509 and showed a trend of positive enrichment in the other two dataset of 
targeted therapy (Figure 4.18A). This is in contrast to what was observed in vitro, where 
undifferentiated cell lines where associated to drug tolerance. The melanoblast-like 
signature was significantly negatively correlated to response to MAPK inhibitors in 
GSE50509 and EGAD00001001306, while showed an opposite behavior in GSE65185. 
For the immunotherapy dataset we observed a positive enrichment of the 
melanoblast-like, and a negative enrichment of the melanocytic and the transitory/CIN 
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signatures in CR patients compared to PR or PD patients. Only the melanoblast-like 
signature maintained its significantly positive enrichment in PR patients compared to PD 
(Figure 4.18A). Additionally, we assessed the association to therapeutic response for a 
very recently published gene sets derived from single-cell RNA-sequencing of melanoma 
tumours during treatment with RAF inhibitors (Rambow et al., 2018). As observed for our 
consensus signatures, the pattern of enrichment is not reproducible across all datasets 
(Figure 4.18B). 
 
Figure 4.18. Assessment of the predictive value of melanoma transcriptional state signatures in clinical 
tumours. A-B) Bubble plots showing the association of selected signatures and response to anti-MAPK and 
anti-PD-1 therapy in publicly available datasets. The size of each circle is proportional to the normalized 
enrichment score calculated by GSEA. 
To get a broader view of the pathways associated to therapeutic response we 
performed GSEA using the HALLMARK collection, a list of gene sets representing well-
defined biological processes (Figure 4.19). Again we observed a certain level of 
inconsistency across datasets but gene sets related to interferon-alpha and interferon-
gamma signaling were found to be positively associated to response for all three datasets 
of targeted therapy and for CR patients compared to PR or PD in the anti-PD-1 dataset. 
Other immune-related gene sets such as inflammatory response and IL6-JAK-STAT3 
signaling showed a trend of positive association in all datasets under investigation. 
These results suggest that the consensus subtypes alone could not predict in vivo 
the response to targeted MAPK inhibition and PD-1 blockade but other factors such as the 
cross-talk between tumour and immune and stromal cells or the presence of additional 
genomic alterations could impact on the therapeutic response. However, we could not 
exclude that the poor performance of consensus subtypes in predicting response and the 
poor reproducibility across datasets arose from the small sample size of available datasets 
and their heterogeneity in terms of sample composition, therapeutic treatment and 
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technological platform used for the transcriptional profiling. Analysis of much larger and 
homogenous cohorts is required for a robust assessment of molecular subtypes of 
melanoma as predictive biomarkers. 
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Figure 4.19. Biological processes associated to targeted- or immunotherapy response. The size of each 
circle is proportional to the normalized enrichment score calculated by GSEA. 
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4.9 Multi-omics characterization of consensus subtypes 
4.9.1 Somatic mutations and copy number aberrations 
According to the mutational pattern of the most frequently mutated genes in 
melanoma (BRAF, RAS and NF1) melanoma can be classified in four genomic subtypes: 
mutant BRAF, mutant RAS, mutant NF1 or triple WT if none of the 3 genes is mutated. 
Here we assessed whether an association between consensus subtypes and genomic 
subtypes existed. We found that beside a higher frequency of BRAF-mutant tumours in 
the neural crest-like group, the four genomic subtypes were distributed across the five 
consensus subtypes indicating that the driver mutated genes in melanoma did not 
contribute to the determination of molecular subtypes at the transcriptional level (Figure 
4.20A). We next investigated the overall mutational pattern of melanoma samples. The 
five consensus subtypes showed a comparable mutational burden (Figure 4.20B). The 
combination of somatic mutations in a tumour can be deciphered in several mutational 
signatures arising from different mutational processes and previously identified through 
genomic analysis of multiple cancer types (Alexandrov et al., 2013b; Alexandrov et al., 
2013a). Many of these signatures are cancer-specific and melanoma is characterized by a 
mutational signature enriched of CC>TT mutations at dipyrimidines photodimers, typical 
of UV damage. We measured the contribution of 30 mutational signatures from COSMIC 
in TCGA-SKCM dataset and we assessed whether any signature was enriched in a 
particular consensus subtype. Three major signatures were identified to contribute to the 
mutational pattern of TCGA melanoma samples. As expected, the most abundant 
signature was the UV-related Signature 7, followed by Signature 1 that is recurrent in all 
cancer types and is correlated to age. Finally, we found Signature 11, another signature 
enriched in melanoma with a pattern of mutation similar to that of alkylating agents. 
None of the signatures was enriched in a specific consensus subtype (Figure 4.20C). We 
finally tested whether other genes beside BRAF, RAS and NF1 were preferentially 
mutated in any of the consensus subtype. After multiple testing correction no statistically 
significant associations were observed. Inspection of the top-associated mutated genes 
(Fisher’s exact test nominal p-value < 0.001) highlighted that their trend of association 
with consensus subtypes could be due chance and not biologically relevant as these 
mutations occurred in a small fraction of patients (Figure 4.20D).  
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Figure 4.20. Somatic mutation analysis of TCGA-SKCM consensus subtypes. A) Distribution of genomic 
subtypes across the five consensus subtypes. B) Mutational load of each subtype measured as the number 
of somatic mutations for each sample on a log10 scale. C) Heatmap showing the relative contribution of 
signatures 1, 7 and 11. The color bar above the heatmap represents the consensus subtype of each sample. 
D) Oncoplot showing the frequency of mutations across subtypes for the genes showing a trend of 
association with consensus subtypes (p < 0.001). Only samples with a mutation in at least one of the genes 
are shown. 
For the same patients we analyzed copy number aberration data. We first 
assessed whether the consensus subtypes differed in terms of tumour cell ploidy and 
purity, inferred from copy number data. Consensus subtypes showed comparable level of 
tumour ploidy (Figure 4.21A) but showed different tumour purity with the 
undifferentiated subtype characterized by the lowest purity. This result was in agreement 
with the tumour purity estimated from gene expression data with the ESTIMATE 
algorithm (Figure 4.11C) and confirmed the high level of stromal component within these 
tumours.  
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Figure 4.21. Tumour heterogeneity based on copy number data. A-B) Box plots showing the ploidy (A) and 
tumour purity (B) estimated by ABSOLUTE algorithm. 
By counting the number of amplifications and deletions we obtained an estimate 
of the chromosomal instability of each tumour (Figure 4.22A). We found that the 
transitory/CIN subtype had on average a higher number of amplifications and deletions, 
supporting the genomically instable phenotype of this subtype. In contrast, the 
undifferentiated subtype was characterized by a lower number of aberrations and 
especially of deletions. However, given the high content of non cancerous cells we cannot 
exclude that in this group several copy number aberrations could be missed due to a loss 
of sensitivity arising from the presence of normal stromal cells. Similarly to mutations, we 
aimed to identify copy number events associated to consensus subtypes. Using GISTIC 
algorithm we first identified significantly recurrent amplifications and deletions across the 
entire TCGA-SKCM cohort. Several genomic regions were found to be significantly altered, 
divided in 17 amplified and 24 deleted regions (Figure 4.22B). Regardless of consensus 
subtype, we found recurrent deletions of CDKN2A (9p21.3) and PTEN (10q23.31) and 
amplification of TERT (5p15.33), MITF (3p13), MYC (8q24.3) and BRAF (7q34). Focusing on 
the significantly altered regions we tested their association with consensus subtypes. Out 
of the 41 regions tested we found statistically significant association for 21 of them. For 
example, we found that deletions at 19p13.3 and 11q23.3 occurred preferentially in the 
melanocytic subtype. Deletions of 10q23.31 and 9p21.3 regions, containing PTEN and 
CDKN2A, respectively, were more recurrent in the undifferentiated subtype. However, 
similarly to somatic mutations, despite these regions were statistically significantly more 
frequent in specific subtypes, we observed that they were recurrent across all of them 
(Figure 4.22C).  
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Figure 4.22. Somatic copy number aberration analysis of TCGA-SKCM consensus subtypes. A) Number of 
amplified and deleted genes identified by GISTIC for samples belonging to different consensus subtypes. B) 
GISTIC plots showing the most recurrently amplified (red) and deleted (blue) regions in the entire TCGA-
SKCM cohort, regardless of consensus subtype. The right bar shows the chromosomal location and on the 
left are reported the regions significantly altered (FDR < 0.05, vertical green line). C) Oncoplot reporting the 
frequency of amplifications (red) and deletions (blue) of the regions found significantly associated with 
consensus subtypes (FDR < 0.05). 
Overall, these results showed that somatic mutations and copy number 
aberrations did not play a critical role in the determination of the consensus subtypes. To 
confirm this hypothesis we performed an integrative analysis of gene expression and copy 
number data. We first correlated the expression of each gene with its copy number 
measurement and the distribution of the Pearson’s correlation coefficients showed a shift 
of the distribution toward positive values (Figure 4.23A). This suggested that the 
expression of several genes was influenced by their copy number status. However, 
according to GSEA, we did not observe any significant enrichment toward the positively 
correlated genes for the consensus subtypes signatures and for GO biological process 
62 
 
terms representative of the main pathways altered in consensus subtypes (Figure 4.23B-
C). 
 
Figure 4.23. Integrative analysis of RNA-Seq and copy number data. A) Distribution of the Pearson’s 
correlation values the expression of each gene and its copy number log2ratio. The green curve is the 
observed distribution, compared to a random distribution obtained by randomly shuffling the genes 1000 
times. B-C) Enrichment plots for selected gene sets tested against the list of genes pre-ranked according to 
the Pearson’s correlation coefficient. The “Gene ranks” column shows the location of the genes included in 
each pathway along the pre-ranked gene list. NES: normalized enrichment score; padj: adjusted p-value. 
4.9.2 DNA methylation 
Gene transcription is heavily influenced by epigenetic modification such as DNA 
methylation. To describe the epigenetic landscape of consensus subtypes we analyzed 
methylation data for TCGA-SKCM samples. Methylation profiles were obtained using 
Illumina Infinium HumanMethylation450K BeadChip arrays that target more than 450,000 
CpG methylation sites along the genome. 
To get a first overview of the methylation status of samples belonging to the 
different consensus subtypes we first performed an explorative analysis by simply 
visualizing the mean methylation level of each sample in function of consensus subtypes. 
The only significant difference was observed between the undifferentiated and neural 
crest-like subtypes with the latter showing a decreased level of methylation (Figure 
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4.24A). We next identified differentially methylated CpG sites comparing each subtype 
with all other four. More than 68000 CpG sites were significantly differentially methylated 
across subtypes (FDR < 0.05 and β fold change > 0.1) mapping on 11673 unique genes. 
However, differentially methylated CpGs were not equally distributed across subtypes but 
were prevalently found in the undifferentiated and melanoblast-like subtypes (Figure 
4.24B). Among the most significantly hyper-methylated sites in the undifferentiated 
subtype we found CpGs located in the nearby region of transcription start site of MITF-M 
transcript variant (Figure 4.24C), which is specifically expressed in melanocytes. 
Due to the high number of differentially methylated sites and the one-to-many 
relationship between genes and CpG sites, a full interpretation of the results is made 
extremely complex. Indeed, many genes have multiple CpG methylation sites distributed 
in nearby regions, inside the promoter and in the gene body and the effect on 
transcription is unknown for the majority of them. Thus, we applied a more general 
approach to understand whether the transcriptional changes of consensus subtypes are 
under epigenetic control. For this purpose, we calculated a single methylation value for 
each gene by averaging the intensities of the probes mapping in the promoter regions 
and we correlated these values to gene expression levels. Overall, we found that the 
observed distribution of the Pearson’s correlation coefficients for matched methylation 
and transcriptomics data was shifted toward negative values (median = -0.08) (Figure 
4.25A). A significant negative correlation between gene expression and methylation level 
was observed for 6838 genes. However, 1847 genes showed a significantly positive 
correlation. According to GSEA, genes found differentially expressed across consensus 
subtypes were enriched toward the genes negatively correlated with their methylation 
status (Figure 4.25B). Moreover, several biological processes previously described as key 
altered pathways in the consensus subtypes were enriched of anti-correlated genes 
(Figure 4.25C). These findings suggested that the expression of genes relevant for the 
biology of consensus subtypes was under DNA methylation control. 
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Figure 4.24. DNA methylation analysis of TCGA-SKCM consensus subtypes. A) Average methylation levels 
of samples within each consensus subtypes. B) Number of significantly differentially methylated CpG sites 
(FDR < 0.05 and absolute β-value fold change > 0.1). Red bars denote methylated CpGs, blue bars 
demethylated CpGs. C) MITF methylation status. The top panel shows MITF locus on chromosome 3 
(vertical red bar) and all MITF transcript isoforms from Ensembl. The black vertical bars in the middle panel 
show the location of CpG sites interrogated by Illumina Infinium450 arrays. The lower panel shows the 
average β-value of the CpG sites along MITF gene in each subtype. The red box highlights the differentially 
methylated CpG probes targeting the nearby region of the transcription start site of MITF-M isoform (MITF- 
ENST00000394351). 
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Figure 4.25. Integrative analysis of RNA-Seq and methylation data. A) Distribution of the Pearson’s 
correlation values the expression of each gene and its methylation level. The green curve is the observed 
distribution, compared to a random distribution obtained by randomly shuffling the genes 1000 times. B-C) 
Enrichment plots for selected gene sets tested against the list of genes pre-ranked according to the 
Pearson’s correlation coefficient. The “Gene ranks” column shows the location of the genes included in 
each pathway along the pre-ranked gene list. NES: normalized enrichment score; padj: adjusted p-value. 
4.9.3 microRNA expression profiling 
MicroRNAs (miRNAs) are small non-coding RNAs implicated in post-transcriptional 
regulation of gene expression through translation inhibition or mRNA target degradation. 
They participate in the regulation of many cellular processes and they are key players in 
many human diseases, including cancer. In addition to cell-intrinsic activity they also 
mediate inter-cellular communication between tumour cells and their microenvironment. 
Given the high level of transcriptional regulation observed across the consensus subtypes 
we analyzed miRNA expression data of TCGA-SKCM samples to define sets of miRNAs 
involved in subtype determination through gene expression regulation. Comparing each 
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subtype with all other four we found many miRNAs significantly differentially expressed 
(FDR < 0.05, Figure 4.26). 
 
Figure 4.26. miRNA expression analysis of TCGA-SKCM consensus subtypes. Volcano plots showing the 
number of differentially expressed miRNAs in each subtype. The x-axis represents the log2 fold change, the 
y-axis the –log10 of the false discovery rate. miRNAs with an FDR < 0.05 (horizontal dashed line) are 
highlighted. Significant miRNAs with an absolute fold change ≥ 1.5 (vertical dashed lines) are highlighted 
with a darker color. Red: up-regulated miRNAs; blue: down-regulated miRNAs. 
Given the high number of differentially expressed miRNAs and the extreme 
complexity of the miRNA-mRNA regulatory dynamics (a miRNA can target multiple 
mRNAs and an mRNA can be targeted by several miRNAs) we applied an integrative 
approach to define the biological role of differentially expressed miRNAs in melanoma. 
We first selected miRNAs and genes significantly differentially expressed across subtypes 
with a fold change of at least 1.5 and 2 in at least one contrast, respectively. Then using in 
silico miRNA target predictions and matched gene-miRNA expression data we identified a 
list of candidate targets for each miRNA. Candidate targets for a miRNA were those 
predicted by at least 2 out of 6 prediction algorithms used and negatively correlated to 
their targeting miRNA (Pearson’s correlation coefficient < -0.2). Each list of candidate 
targets was then tested for significantly enriched pathways (FDR < 0.05). Finally, we 
identified clusters of miRNAs involved in the same pathways using hierarchical clustering 
and Jaccard index as similarity measure. Using this approach we found seven clusters of 
miRNAs targeting genes involved in the same biological processes (Figure 4.27A). To 
assign a biological function to each cluster we investigated the pathways more frequently 
enriched in the target list of each miRNA (Figure 4.27B). Clusters 1, 2 and 6 included the 
majority of miRNAs down-regulated in the undifferentiated and neural crest-like 
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subtypes. The anti-correlated targets of these miRNAs were enriched in immune-related 
processes and extra-cellular matrix remodeling, in line with the observation from gene 
expression that the two invasive subtypes over-expressed immune and stromal genes. On 
the other side, clusters 4, 5 and 7 contained miRNAs up-regulated in the undifferentiated 
and neural-crest subtypes whose targets were implicated in pigmentation and 
melanocyte differentiation. Finally, cluster 3 was populated of miRNAs characterized by a 
poor degree of shared pathways both with miRNAs of the same cluster and with all other 
miRNAs. 
For each cluster we focused our attention on the top-5 miRNAs most differentially 
expressed across consensus subtypes and for each miRNA we reported the top-5 anti-
correlated targets (Figure 4.28). Among the 15 top differentially expressed miRNAs of 
clusters 1, 2 and 6, up-regulated in melanoblast-like and melanocytic subtype, 11 were 
members of the miR-506-514 cluster (hsa-miR-508-5p, hsa-miR-508-3p, hsa-miR-509-5p, 
hsa-miR-509-3p, hsa-miR-510-5p, hsa-miR-514a-3p and hsa-miR-514b-3p) that along with 
hsa-miR-211-5p were shown to be melanocyte-specific miRNAs (Boyle et al., 2011; 
Streicher et al., 2012). Among the top differentially expressed miRNAs of clusters 4, 5 and 
7, up-regulated in the undifferentiated and neural crest-like subtypes we found members 
of the miR-143/145 cluster (hsa-miR-143-5p and hsa-miR-145-5p), miR-199/214 cluster 
(hsa−miR−199a−5p, hsa−miR−214−3p), miR-100 cluster (hsa−miR−125b−5p and 
hsa−let−7a−2−3p) and miR-181 cluster (hsa−miR−181d−5p and hsa−miR−181c−3p). MITF 
and several of its target genes such as BCL2, MBP, CAPN3 and TYR were among the top 
anti-correlated predicted targets of these miRNAs. Other members of miR-199/214 and 
miR-100 clusters were among the top-5 miRNAs up-regulated in the two invasive 
subtypes and fell in cluster 3. Among the top anti-correlated targets of hsa-199a-3p, hsa-
miR-199b-3p and hsa-miR-214-5p there was TFAP2A. It was previously shown that miR-
214 increases migration and invasion of melanoma cells by silencing TFAP2A and TFAP2C 
(Penna et al., 2013). In addition these miRNAs are anti-correlated with well known MITF 
targets such as MLANA, MLPH and VAT1. CABLES1, an important regulator of cell cycle, is 
targeted by many miRNAs up-regulated in the undifferentiated and neural crest-like 
subtype. 
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Figure 4.27.Pathway analysis of miRNAs differentially expressed across consensus subtypes. A) Heatmap 
of the Jaccard index values calculated for each pair of miRNAs on the basis of the shared pathways. Column 
and row dendrograms were obtained by hierarchical clustering of the Jaccard indices (Euclidean distance, 
Ward linkage). The color bars on the top represent the 7 identified clusters and the up- or down-regulation 
of the miRNAs in each consensus subtype. B) Bar plot of the top-5 most frequently enriched pathways (FDR 
< 0.05) in each cluster of miRNAs. 
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Figure 4.28. Top-differentially expressed miRNAs and related targets. The heatmap on the left shows the 
log2 fold changes across consensus subtypes of the top-5 most significantly differentially expressed miRNAs 
for each cluster identified in Figure 15A. The heatmap on the right report the top-5 anti-correlated 
predicted target genes of the miRNAs on the left. The color scale is proportional to the Pearson’s 
correlation coefficient of the miRNA-target pair. 
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5 DISCUSSION 
In this thesis we assessed the consistency of nine melanoma gene expression 
signatures through a harmonized classification of large datasets of melanoma clinical 
tumours and cell lines and we derived the consensus molecular subtypes of melanoma. 
Gene expression-based classifications in melanoma have been previously reported and 
led to the identification of up to four melanoma subtypes, distinguished by proliferation 
rate, invasive capability and differentiation status. In addition to technological and 
analytical differences, these signatures were derived from in vitro cell lines, clinical 
tumours or a combination of both, thus increasing the level of complexity. The overlap 
and robustness of these classifications remains unknown. 
5.1 Identification and characterization of melanoma consensus 
subtypes 
Lauss and colleagues (Lauss et al., 2016) already carried out an attempt to compare 
different melanoma classifications, even if they focused only on two subtyping schemes. 
They compared their melanoma subtypes (Jonsson et al., 2010) with those of TCGA (The 
Cancer Genome Atlas Network, 2015) and they found a certain degree of overlap in the 
classifications despite the two gene signatures were poorly overlapping. When we 
measured the overlap between the nine gene signatures considered in our work we 
found similar results. No genes were found to be represented in all nine signatures and 
only 30 were present in more than 50% of signatures. This core of 30 genes included MITF 
and many of its targets, indicating that the MITF transcriptional network, which regulates 
the phenotype switching from the invasive to the proliferative cell state (Hoek et al., 
2008; Hoek and Goding, 2010), is captured by the majority of signatures. The signatures 
lacking MITF and its target genes could include other genes correlated to phenotype 
switching, thus explaining the poor overlap among them. Shifting from a gene- to a 
pathway-level did not show a relevant increase in signatures’ similarity, with a few 
exceptions. We hypothesize that this analysis is limited by the incomplete knowledge of 
gene functions and by the problem of correlated variables in high-throughput studies. Not 
all genes, indeed, are currently assigned to a pathway and this can negatively impact the 
outcome of a pathway analysis. A clear example comes from the TCGA classification: 
despite the keratin and MITF-low subtypes differ in the expression of genes related to 
melanocyte development, pigmentation signaling and melanin synthesis, neither MITF 
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nor its target genes were found in TCGA signature. This shows that the genes included in 
TCGA signatures are correlated to MITF but they are not categorized into melanocyte or 
pigmentation pathways. 
Despite the inconsistencies among the nine gene signatures we observed a high 
degree of concordance in sample classifications indicating that different subset of genes 
capture the same underlying biology of melanoma subtypes. Our analytical framework 
confirmed that the dual invasive/proliferative classification can be further refined in two 
additional biologically relevant subgroups, in agreement with previous reports (Dugo et 
al., 2015; Tsoi et al., 2018). Moreover, through our approach we were able to identify a 
previously undescribed subtype composed of samples that, according to the existing 
melanoma classifiers, had an undetermined classification. Two of our five subtypes, the 
undifferentiated and the neural crest-like were characterized by an invasive phenotype, 
while the other two, the melanoblast-like and the melanocytic subtypes correlated with 
signatures of proliferation. The newly identified subtype, named transitory/CIN, showed a 
negative correlation with both invasive and proliferative signatures and had an 
intermediate expression of markers of both phenotypes. These observations led us 
hypothesize that this subtype is representative of an intermediate phenotype between 
the two cell states, hypothesis sustained by the finding that this subtype is located in the 
middle of the melanocyte differentiation trajectory and reflects a late neural crest/early 
melanoblast state. Altogether these results suggest that melanoma cells can adopt 
intermediate states between the invasive and proliferative states; however we cannot 
exclude that these transcriptional patterns arise from an admixture of invasive and 
proliferative cells within the same tumour that confounds gene expression signals. 
In line with previous findings (Dugo et al., 2015; Tsoi et al., 2018) samples of the 
undifferentiated subtype showed the lowest expression of MITF, ERBB3 and SOX10 and 
the highest expression of AXL and EGFR, both at the gene and protein level as identified 
by our proteomic analysis. The invasive phenotype of the undifferentiated subtype was 
confirmed by the up-regulation of SERPINE1, ANX1, and CAV1 shown to be involved in 
invasiveness of melanoma cells (Boudhraa et al., 2014a; Boudhraa et al., 2014b; Lobos-
Gonzalez et al., 2013; Lobos-Gonzalez et al., 2014; Verfaillie et al., 2015). In addition, the 
undifferentiated subtype was characterized by a strong presence of immune components, 
both assessed by pathway analysis and gene expression deconvolution. This finding 
supports the notion that melanoma cell states directly influence the tumour 
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microenvironment and the high immune infiltration of the undifferentiated subtype could 
reflect a mechanism similar to the inflammation-induced dedifferentiation observed in in 
vivo and in vitro models (Landsberg et al., 2012; Holzel and Tuting, 2016). According to 
this model, MITF represses the pro-inflammatory response by negatively regulating c-JUN 
expression. Tumours lacking MITF are hyper-responsive to TNF-α due to active c-JUN and 
elicit a pro-inflammatory response through extensive recruitment of myeloid immune 
cells within the tumour microenvironment (Riesenberg et al., 2015). The undifferentiated 
subtype fits well to this model as it showed down-regulation of MITF, up-regulation of 
JUN and TNF (data not shown), and abundance of pro-tumourigenic macrophages M2. In 
contrast with this, we observed also a higher abundance of anti-tumour CD8+ T-cells in 
this subtype, especially in comparison with the neural crest-like. However, the presence 
alone of cytotoxic T-cells does not indicate an active anti-tumour response. Markers of 
immune inhibition (CTLA-4, PD-1 and PDL-1) were indeed up-regulated in this subtype, 
together with signatures of T-cell exhaustion (Tirosh et al., 2016) (data not shown), 
suggesting that undifferentiated tumours can escape immune surveillance. 
The neural crest-like subtype was distinguished by a marked expression of genes 
involved in extracellular matrix remodeling and migration, in addition to markers of 
neural crest cells. At the protein level this subtype showed up-regulation of proteins 
related to invasiveness such as fibronectin (Olbryt et al., 2011; Wouters et al., 2014), the 
integrin CD49b (Yoshimura et al., 2009; Knutson et al., 1996) and PKC-alpha (Byers et al., 
2010) in concert with loss of the epithelial marker E-cadherin. We found also up-
regulation of ASNS, a known target of the transcription factor ATF4, a key mediator of the 
integrated stress response that is essential in the establishment of the invasive phenotype 
(Falletta et al., 2017). 
The proliferative state was divided in the melanoblast-like and the melanocytic 
subtypes with both expressing markers of pigment cell differentiation and pigment 
biosynthesis. According to the rheostat MITF model (Carreira et al., 2006; Goding, 2011; 
Hoek and Goding, 2010), cells expressing MITF can proliferate or differentiate depending 
on MITF levels and MITF post-translational modifications. Here we found that the 
melanocytic subtype recapitulated the fully differentiated state of melanocytes and was 
characterized by over-expression of metabolic genes involved both in glycolysis or 
oxidative phosphorylation. While these two mechanisms are considered alternative 
processes in normal cells it has been shown that they can coexist in cancer cells, thus  
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increasing cell plasticity (Yu et al., 2017). The melanoblast-like subtype represented the 
preceding step of fully differentiated melanocytes. While genes involved in cell 
proliferation were up-regulated in both proliferative subtypes, we found a specific up-
regulation of genes related to DNA methylation, mRNA transcription and processing 
indicating a strong transcriptional activity in the melanoblast-like subtype. 
The transitory/CIN subtype showed up-regulation of chromatin remodeling, 
meiotic and cancer-testis genes. The expression of meiotic genes in mitotically dividing 
somatic cells is a phenomenon called meiomitosis and it can disrupt the mechanisms that 
control chromosome maintenance and segregation generating chromosomal instability 
(Lindsey et al., 2013; Rosa et al., 2012; McFarlane and Wakeman, 2017). In line with this, 
we found a positive enrichment in this subtype of a chromosomal instability signature. 
However, the relation between chromosomal instability and phenotype switching 
remains unclear. 
5.2 Prognostic relevance of melanoma consensus subtypes 
In addition to being biologically relevant, we obtained evidences that consensus 
subtypes are determinants of prognosis in stage III/IV melanoma patients. The 
melanocytic and the transitory/CIN subtypes were characterized by the worst prognosis 
while the undifferentiated and the neural crest-like subtype were associated to a better 
outcome. Our findings are in agreement with previous reports showing that proliferative 
and invasive tumours were associated with poor and good outcome, respectively 
(Jonsson et al., 2010; Rambow et al., 2015; The Cancer Genome Atlas Network, 2015). 
However, our classification may provide a better stratification of patients. For instance, 
the proliferative melanoblast-like subtype showed a better outcome compared to the 
proliferative melanocytic subtype, despite not statistically significant. These findings 
suggest that the biological differences between two subgroups of the same phenotypic 
state may affect the outcome of patients. We also showed that the tumour immune 
infiltration has a critical prognostic role. As previously reported (Jonsson et al., 2010; 
Bogunovic et al., 2009; The Cancer Genome Atlas Network, 2015), we found that a high 
level of tumour immune infiltration is positively associated to outcome. In consideration 
of that, one would expect the undifferentiated subtype to have the best prognosis due to 
its high level of immune infiltration. However, despite not significantly, the neural crest-
like subtype showed a better survival compared to the undifferentiated subtype. This 
behavior could be explained by the differences of immune cell types observed between 
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these two subtypes. These results indicate that for prognostic purposes one should 
consider not only the level of immune infiltration but also its immunosuppressive or pro-
immunogenic state and possibly its spatial location within the tumour microenvironment. 
5.3 Predictive value of melanoma consensus subtypes 
We also focused our attention on the possibility to use our consensus classification 
to predict response to therapy. Identification of predictive biomarkers is often pursued 
through pharmacological studies on in vitro cell lines. It is thus important that cell lines 
are representative models of clinical tumours. Here we showed that the five consensus 
subtypes identified in tumours are recapitulated in melanoma cell lines and present 
similar gene expression alterations. 
Phenotype switching is directly linked to MAPK inhibitors resistance with invasive 
cells being more drug-tolerant. Depending on its levels, MITF expression was associated 
to both resistance and sensitivity to MAPK inhibitors (Johannessen et al., 2013; Haq et al., 
2013). The consensus classification fits to this model showing that there is no linear 
dependence between MITF expression and sensitivity to MAPK inhibitors. As we 
previously reported, BRAFV600E mutant cell lines of the undifferentiated subtype were the 
most resistant to BRAF inhibitors and the neural crest-like subtype contained both 
sensitive and resistant cells. Moreover, we observed a different sensitivity between the 
melanoblast-like and melanocytic subtypes with the latter having higher levels of MITF 
and higher tolerance to BRAF inhibitors on average. This is in agreement with the rheostat 
model according to which low levels of MITF induce a slow-cycling invasive phenotype 
resistant to MAPK inhibitors, intermediate MITF levels enhance proliferation and confer 
susceptibility to MAPK inhibitors, whereas high MITF expression induces differentiation-
mediates senescence and drug resistance (Carreira et al., 2006; Ahn et al., 2017). 
Unfortunately, no conclusions can be drawn for the transitory/CIN subtype as only one 
BRAFV600E cell line fell into this subtype. However, this cell line was sensitive to BRAF 
inhibitors treatment. 
Beyond BRAF inhibitors we observed that the meiomitotic transitory/CIN subtype 
was the most sensitive to YM-155 and BI-2536. YM-155 is a small-molecule inhibitor that 
blocks survivin (BIRC5) through direct binding to its promoter and induces apoptosis 
(Nakahara et al., 2007). BI-2536 is another small-molecule inhibitor that inhibits PLK1 
(Steegmaier et al., 2007). Both these proteins, which were up-regulated in this subtype, 
play a key role in regulation of cell cycle and maintenance of chromosomal stability during 
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mitosis in proliferating cells and their up-regulation promotes cell survival (Colnaghi and 
Wheatley, 2010; Feng et al., 2009). The melanocytic subtype showed higher sensitivity to 
a series of HDAC inhibitors, a class of drugs that was shown to repress the expression of 
MITF (Yokoyama et al., 2008). Taken together these findings show that each consensus 
subtype is specifically sensitive to different drugs and in vitro pharmacogenomic datasets 
could be useful resources for identification of new druggable targets and alternative 
therapeutic strategies for tumours refractory to conventional therapies. However, we 
would like to point out that, despite we found statistically significant associations 
between consensus subtypes and drug sensitivity data, the range of sensitivity values 
within each subtype was remarkably wide. This indicates that the consensus classification 
alone is not an accurate predictor of drug resistance and other determinants of drug 
tolerance should be considered for a better prediction. 
The predictive role of consensus subtypes was totally lost when we analyzed 
response to BRAF inhibitors in metastatic melanoma patients. According to the 
observations obtained in vitro, one would expect a negative correlation between best 
overall response and the undifferentiated subtype and a positive correlation with the 
transitory/CIN or melanoblast-like subtypes. However, assessment of the correlation 
between subtypes signatures and response to therapy showed inconsistent results within 
and between datasets, thus preventing us to draw any reliable conclusion. Several 
biological and technical factors could explain these negative results. First, it is known that 
phenotypic plasticity is only one of the many mechanisms that confer drug tolerance to 
melanoma cells. Of consequence, the therapeutic response of each patient depends not 
only on the transcriptional state of the tumour but also on other genetic alterations that 
could not be considered in the analyses we performed due to the lack of such 
information. These additional mechanisms include the composition of the tumour 
microenvironment and the cross-talk between tumour, stromal and immune cells. The 
positive enrichment of immune-related genes, and in particular of the interferon-α/γ 
pathways, in patients showing better response was the most consistent finding across the 
datasets we analyzed. How the immune systems influences the response to targeted 
therapy remains unclear, but our observations in conjunction with previous reports (Hugo 
et al., 2015), highlight the importance of considering the immune status of tumours when 
predicting targeted drug treatment response. Another factor that could contribute to the 
discrepancy between in vitro and in vivo results is related to the measurement of drug 
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efficacy. In in vitro pharmacological studies, drug response can be reported using 
different statistics, such as AUC or half maximal inhibitory concentration (IC50), but all of 
them are a direct measure of the amount of cancer cells killed by the treatment. In solid 
tumours instead, treatment efficacy is clinically measured using the best overall response, 
defined by the RECIST criteria (Eisenhauer et al., 2009), that is evaluated by taking into 
account the change in size and number of target (measurable) and non-target (non 
measurable) lesions at baseline and at regular time-points during treatment. Thus, best 
overall response is a measure of the response to treatment of patient, not of the single 
lesion. It is thus possible that the tumour specimen used for pre-treatment genomic 
profiling is not representative of the measured patient’s response. Of consequence, trying 
to make a parallelism of treatment response between in vitro cell lines and clinical 
tumours may lead to misinterpretations. Finally, we challenge the adequacy of the 
currently available datasets used to assess the predictive relevance of consensus 
subtypes. The sample size of these datasets is very limited reducing the statistical power 
and the robustness of the analyses. They include patients treated with different BRAF 
inhibitors and in some cases with combinatorial therapy of BRAF and MEK inhibitors. 
Tumour specimens were collected from metastases located at different anatomical sites 
that could differ in levels of stromal or immune contamination. All these aspects add 
further level of variability that can negatively impact downstream analyses. On the basis 
of these observations, our analyses remain explorative and we believe that any 
conclusions should be drawn with caution. 
5.4 Multi-omics data analysis of melanoma consensus subtypes 
The availability of multiple types of high-throughput data for the same subjects 
allowed us to exclude significant association between the consensus subtypes and 
mutational status of all genes, mutational load, and mutational signatures. The 
independence of phenotype-specific gene expression from BRAF mutational status was 
already reported in the first works of Hoek and colleagues (Hoek et al., 2006; Widmer et 
al., 2012). The melanoma genomic and transcriptomic subtypes identified by TCGA were 
completely unrelated (The Cancer Genome Atlas Network, 2015). Through the analysis of 
copy number data we showed that our consensus subtypes do not differ in terms of 
ploidy but present varying degree of chromosomal instability, with the transitory/CIN 
subtype harboring a higher number of focal amplifications and deletions. Despite both 
aneuploidy and chromosomal instability confers genomic instability and contribute to the 
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evolution and heterogeneity of cancer cells, they represent related but different 
mechanisms that are not necessarily correlated (van Jaarsveld and Kops, 2016). We argue 
that the higher chromosomal instability in this subtype is a consequence of errors that 
were expanded over different cell divisions occurring in this meiomitotic phenotype. We 
identified many regions frequently amplified or deleted across patients. These copy 
number aberrations include amplifications of oncogenes, such as MITF, AKT3, MDM2 and 
MYC in addition to amplifications of TERT and BRAF and deletions of tumour-suppressor 
genes such as PTEN, CDKN2A and STK11. Some of these regions were found to be 
statistically significantly associated to consensus subtypes. For example the region 
containing CDKN2A was more frequently deleted in the neural crest-like subtype and less 
often in the undifferentiated subtype. Despite the statistical significance, looking at the 
frequencies across subtypes of these regions, and the lack of a positive correlation 
between expression and copy number status of genes representative of consensus 
subtypes, made us conclude that copy number events could minimally contribute to the 
definition of the transcriptional state of melanoma cells. 
An opposite situation was found when we analyzed DNA methylation and miRNA 
expression data. Hundreds of CpG sites were differentially methylated across the five 
consensus subtypes and many of them were negatively correlated with the expression 
levels of genes included in the consensus subtype signatures. We also found many genes 
whose expression levels were positively correlated with their methylation status. This 
suggests that gene methylation is only one of the multiple mechanisms that control 
expression and its effect could depend on the genomic context of methylation sites. 
Another possible explanation is that these genes are under a different transcriptional 
control or the functional effect of methylation could be masked by the effect of other 
alterations such as mutations or copy number alterations. A large number of miRNAs 
showed a strong deregulation across consensus subtypes. The most differentially 
expressed miRNA was hsa-miR-211-5p, known to inhibit melanoma invasion and to be 
under direct control of MITF via its host gene TRPM1 (Bell et al., 2014; Mazar et al., 2010; 
Levy et al., 2010). Many miRNAs were found to act in a synergistic way as they targeted 
the same genes and consequently the same pathways. Other miRNAs instead showed a 
more specialized regulatory function each targeting specific pathways. Here, we provided 
a general overview of the molecular alterations underlying these biological entities but a 
further in deep characterization of genomic abnormalities is necessary to uncover 
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relevant functional aspects of the disease and drive effective drug development 
strategies.  
6 CONCLUSIONS 
Our results showed that melanoma gene expression classifications converged on 
five fundamental biological entities with distinct transcriptional, epigenomic and 
microenvironmental features, adding new insights to the knowledge of the disease. 
Among them, the transitory/CIN melanoma subtype was a previously unrecognized entity 
characterized by features of genomic instability and expression of cancer-testis antigens. 
Furthermore, analysis of multi-omics data indicated that phenotypic plasticity of 
melanoma cells was not determined by acquisition of specific mutations or other genomic 
alterations, which are irreversible, but it was the result of a transient transcriptional 
reprogramming under tight epigenetic control. Genomic abnormalities can confer to 
melanomas an additional degree of heterogeneity that can sustain cancer cell fitness and 
evolution. Assessing more deeply the molecular features that distinguish these 
melanoma subtypes would uncover relevant functional aspects of the disease, thus 
providing candidate biomarkers and driving effective drug development strategies.  
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